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CHAPTER 1: INTRODUCTION: FOLATES IN HUMAN HEALTH
1.1 The identification and isolation of folate
The functional importance of many essential vitamins and minerals, including Vitamin B9,
folicin or folic acid, was unearthed by rigorous studies that examined associated pathologies that
resulted from nutrient deficiencies.

The history of folates in human health originates in

hematology. At this time, investigating the impact of diet on human disease was emerging, with
much emphasis being placed on what we now know as nutritional anemias.1,2 Macrocytic anemia,
a subclass of megaloblastic anemia, was prevalent among pregnant women in impoverished
communities whose access to proteins, vegetables and fruits was limited.1 This specific type of
anemia is characterized by enlarged erythrocytes which is thought to be a product of impaired
DNA synthesis in red blood cells; a cell type with a high rate of turnover.3,4 In observing the
effects of diet in this condition on albino rats and monkeys, Dr. Lucy Wills and colleagues
discovered that the administration of yeast, yeast extract ( Marmite™) or crude liver extract to
individuals subjected to a diet deficient in B vitamins, ameliorated the anemic condition.1,2,5 This
extrinsic factor contained in yeast was later called “Wills’ factors” by Drs. Janet Watson and
William B. Castle. Through the examination of multiple case studies of macrocytic anemia treated
with different fractions of liver extract and beef muscle, Watson and Castle concluded that there
was an additional component/ factor present that was responsible for assuagement of marocytic
anemia that was different from that which cured Addisonian anemia (pernicious anemia).5,6
Unbeknownst to the scientists of the time, yeast, plants and other microorganism are cable of de
novo folate biosynthesis and the liver is the primary site of the body’s folate storage.7,8 Based on
the empirical clinical data, there was an eruption of critical studies that examined the treatment
potential of liver extract (given orally or parentally) in anemia, which in turn gave rise to multiple
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names for folate, based solely on the animal used in the experiment. These included M factor
(monkeys), vitamin Bc (chickens), Lactobacillus casei factor, and anti-anemia factor, to name a
few. The nomenclature used to describe folic acid or folates has undergone many iterations with
it being named pteroylglutamic acid due to the presence of a pteridine. The current name, folic
acid or folates, was not used until the 1940’s, upon isolation and identification of the compound
in green leafy vegetation.1,5,9
Folate was first isolated from spinach leaves in 1941 by Herschel Mitchell and colleagues and
was eponymously named folic acid after the Latin word folium that translates to leaf.1,10,11 In
1943, E. L. Robert Stokstad and colleagues isolated this very same “factor” from the liver that
promoted the growth of Lactobacillus casei.1,12 Stokstad synthesized the first pure crystal form of
the unconjugated compound, and from that, he was able to reveal important structural information
about the molecule. During his tenure at Berkley’s Nutritional Science department, Stokstad began
seminal research on folic acid metabolism. Stokstad’s research serves as the foundation for
antifolate drug development as he identified many of the enzymes involved in the folate metabolic
cycle nearly 34 years ago (1979).5 This early work was credited for leading to the development of
the first antifolate, aminopterin (4-aminopteroic acid) (AMT).
Today, folates are well recognized for the role they play in human health, growth and
development.13 One of many well documented examples of the impact of folates on human health
is the indisputable role that the vitamin plays in the full development and closure of the neural tube
during days 21-28 post-conception or embryogenesis.14 Adequate folate supplementation in
pregnant women has been thought to lead to the prevention of congenital malformations of the
central nervous system and consequently a decrease in infant mortality and morbidity as neural
tube defects (NTDs) are only second to cardiac defects as the most common congenital
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malformations.15

The abundance of landmark studies that supported this notion lead to a

mandatory implementation of folic acid fortification in grain products in the United States.15 The
resulting rapid decline in infants born with spina bifida or anencephaly, as a consequence of neural
tubes defects, demonstrated the importance of folate in early development.14,15

Moreover,

deficiencies in this vitamin and mutations in genes associated with folate absorption and/or
metabolism have been linked to other disease states and disorders such as vascular disease, certain
subtypes of cancer and Alzheimer’s disease.4 This provided concrete evidence that folates were
vital to the preservation of normal cellular physiology and were a critical component to human
health.
1.2 Folate biology and chemistry
Many anabolic pathways require the addition or modification of carbon groups. Folates are
coenzymes that participate in the metabolism of amino acids and nucleotides by donating or
transferring the required carbon units, which is referred to as one-carbon metabolism.9,13 Because
folate metabolism plays an integral part in the movement of carbon, it has been described by many
as the cornerstone of one-carbon metabolism.13,16,17 One-carbon metabolism is thought to be
comprised of three distinct but interwoven metabolic cycles, the folate metabolic cycle, the
methionine cycle and the trans-sulfuration pathway.18-20 The unifying feature of these three
pathways is the transfer of active one carbon units in a number of enzymatic reactions.
Folate is a generic term that describes any compound that participates in similar cellular
activities as the vitamin that results in the production of amino acids, purine nucleotides and
thymidylate.21,22 This includes naturally occurring folates in foodstuffs, enzymatically converted
species and the synthetic derivative folic acid.21,22 The chemical name of the non-conjugated
vitamin (containing a single γ glutamate residue) is pteroylmonoglutamate (PteGlu).17 This
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molecule is comprised of three groups, including (1) a pterin moiety, which has a methylene group
linage at the 6th position to a (2) para amino benzoyl group and (3) L-glutamatic acid.17 The
pteridine ring is of great functional importance in the metabolism of this vitamin. The two nitrogen
atoms placed on the ring favors reduction product that leads to di and/or tetra hydrogenation of the
ring (Figure 1.1).
Folates destined for intracellular accumulation undergo extensive metabolism to assume their
role as cofactors in physiological reactions.8,17,19 This metabolism is thought to principally involve
the reduction of the pteridine ring (Figure 1.1) (which introduces an asymmetric center at the C6
position), polyglutamylation (the successive addition of glutamate moieties to the γ-glutamyl of
the parent molecule) and the transition to oxidative or reductive states.9,19,23,24 These reactions
give rise to a number of active tetrahydrofolate (THF) forms that are distinguishable by the
substituents they carry at the N5 or N10 positions.8 They can include methenyl (CH+), methylene
(CH2), methyl (CH3), formyl groups (CHO) and formimino (CH=NH) (Figure 1.2).8 The active
tetrahydro forms are the only species that can readily donate or accept single carbons units.8,19
Naturally occurring folates exist as reduced folylpolyglutamates when within the cell, in which
there are multiple glutamate moieties attached to the γ-carboxyl end of the folate molecule.19,23
The most prevalent form of folate identified in mammals is reduced 5-methyl tetrahydrofolate.25,26
In contrast, the synthetic vitamin used in food fortification, folic acid, is fully oxidized and tends
to be less labile than naturally occurring folates, which become less stable with oxidation.9
Because of this, naturally occurring folates and folic acid have a different point of entry in the
metabolic cycle.
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Folic Acid

Pyrazine ring

Folic acid is reduced by DHFR to produce the
enzymatically active tetrahydrofolate species
active tetrahydrofolate

Adapted open access figure, with permission of Carolyn Tam et al.27 Copyright (2012)
“Circulating Unmetabolized Folic Acid: Relationship to Folate Status and Effect of
Supplementation,” Obstetrics and Gynecology International, vol. 2012, Article ID 485179, 17
pages, 2012.
Figure 1.1: The reduction of folic acid. Above is the structure of the folic acid, a synthetic
derivative of naturally occurring forms found in legumes, green leafy vegetables and some fruits.
Folic acid is comprised of three major groups including 1) pteridine 2) para benzoate and glutamic
acid moieties. Folic acid enters the folate metabolism cycle at the site of dihydrofolate reductase,
which acts to reduce the pyrazine ring of the pteridine group resulting in a dihydrofolate form.
This dihydrofolate undergoes an additional reduction through the same enzyme to produce the
active tetrahydrofolate co-enzyme that participates in one-carbon metabolism.
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Tetrahydrofolate
(THF): Major carrier
molecule

10

N - Formyl THF
Oxidation of
formate
(most oxidized)

5

N - Methyl THF:
Oxidation of
methanol
(least reduced)

5

5

N -Formimino THF

10

N , N -Methylene THF:
Oxidation of
formaldehyde

5

10

N , N MethenylTHF

Adapted from Themedicalbiochemistrypage.org, Dr. Michael King copyright (1996-2014)
Figure 1.2: Enzymatically active folate metabolites. This figure highlights multiple forms of
active folate derivatives. Each metabolite differs in the oxidation state of the acquired substituent
and the location of substituent. These metabolites play distinct roles in folate metabolism which
result cellular stores of serine, glycine, purines, methionine and thymidylate.
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There are multiple enzymes and binding proteins involved in folate metabolism that act to
regulate folate homeostasis in tissues through a complex system of feedback loops, substrate
specificities and allosteric regulation.19 These reactions have a global impact on the cell by
affecting both genomic and physiological aspects of function.15,28 The epicenters of folate
mediated one-carbon metabolism reside in the cytoplasm, the mitochondria and the nucleus
(Figure 1.5).17,29 Cytoplasmic one-carbon metabolism has been studied extensively with welldocumented and detailed studies exploring the mechanics of folate metabolism in this
compartment.8,17,19 While our knowledge remains limited for both mitochondrial and nuclear
folate metabolism, there is a growing surge of attention directed towards these two compartments
with the hope of gaining a complete picture of the role of folates in cellular physiology. The
primary source for carbon units used in cytoplasmic one-carbon metabolism is believed to
originate from the one-carbon metabolism that occurs in the mitochondria which is estimated to
contain 40% of the total intracellular folates.20,25 While knowledge is limited on nuclear folate
metabolism, studies with a radio-labeled folate precursor suggest that 10% of total cellular folates
reside in the nucleus.20
Upon cellular entry, naturally occurring folates derived from leafy materials in foodstuff
exist as 5-methyl THF polyglutamates, but begin their journey across the cell membrane in the
monoglutamate transport form.19,26

Mammalian serum/plasma contains folate conjugases/γ-

glutamyl hydrolases, which strip the once polyglutamylated vitamin of additional glutamates at
the gamma carboxyl end of the molecule, resulting in mono-glutamylated folates in the blood and
urine.19 Folates carry a slight negative charge due to ionization of the dicarboxcyclic acid tail,
thereby requiring some form of transmembrane transport to gain intracellular entry.19,25,26
Following intracellular translocation through a specified mechanism of folate transport, folates are
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then subjected to polyglutamylation performed by the cytosolic enzyme folylpoly-gammaglutamate synthetase (FPGS).19 Polyglutamylation via FPGS was validated as an essential step in
folate metabolism through the examination of the Chinese hamster ovary (CHO) cell lines that
were auxotrophic for glycine, thymidine and purines, (CHO AUX B1 cells). 19,23 These cells were
discovered to lack polyglutamylated folates due to the absence of FPGS activity, consequently
resulting in a low intracellular folate pool.19,23 This provided evidence of a dependency or
requirement for these cells to obtain products of folate metabolism/one carbon metabolism from
exogenous sources.19,23

More recently, studies that investigated the anti-tumor activity of

antifolates in cells with augmented human FPGS, reported that cells with increased expression of
the FPGS protein showed enhanced sensitivities to antifolates.30,31 Alternatively, the loss of FPGS
expression and/ or activity has been elucidated as a probable mechanism in antifolate resistance.32
In addition to serving as a mechanism of cellular retention, polyglutamylation also aids in
folate homeostasis by providing a layer of regulation by controlling substrate specificity.17 The
step-wise addition of glutamates at the tail of intracellular folates by FPGS has been well
documented.18,19 The extent of polyglutamylation that can differ among intracellular folates is
thought to create competition with the lower or monoglutamylated species for which the affinity
is higher when compared to extensively glutamylated species for which the Km has increased.18,19
In general, increasing the length of the polyglutamate tail is associated with an increased affinity
to enzymes involved in these pathways with the exception of DHFR.17 There is a clear correlation
between affinity and polyglutamylation. However there is a plateau or change in kinetics for the
heptaglutamylated species, which is the predominant form in humans.19,33 Curiously, some of
these highly glutamylated folate metabolic products can act as inhibitors towards other metabolic
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enzymes within this pathway.17 This highlights the product-driven regulation of one-carbon
metabolism that occurs within the folate cycle.
Another important feature of polyglutamate tail is the role it plays in the “channeling” of
substrate.17,34,35 Channeling is described as the sequential movement of substrate from one enzyme
to another without exposure or release into the surrounding solvent.29,36 Channeling is thought to
add an additional layer of regulation in one-carbon metabolism due to the formation of enzyme
complexes necessary to produce the end product.20,34

Many investigators studying folate

metabolism, more specifically the enzymology associated with this complex and sophisticated
system, have proposed and supported the theory of the formation of a “metabolon” commonly
referred to as the “purinosome”.29 The purinosome has been described as a dynamic multi–enzyme
complex that forms in the cytoplasm during the G1 phase of the cell cycle that facilitates de novo
purine synthesis.29 While metabolic compartmentalization in organelles has been suggested to
serve as a regulatory mechanism, the temporal and spatial assembly of such multi-enzyme
complexes plays a role in directing the activation these pathways.20 Folates with extended
polyglutamyl tails are believed to participate in this distinct type of metabolic partitioning.19,34,37,38
Experts postulate that such channeling evolved not only to increase the efficiency of this metabolic
pathway but to also protect labile intermediates that would be rendered inactive due to extensive
oxidation.19,20,34,36 With this in mind, when surveying enzyme activity within this pathway, in situ
methods are more likely to accurately recapitulate the physiological picture as the channeling
process will be uninterrupted and the natural abundance of multiple polyglutamylated species
would be present.
Intracellular polyglutamylated folate species are the primary molecules that are prepared
to engage in cellular interactions with enzymes in one-carbon metabolism. 17 Many reviews on
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one-carbon metabolism have separated these enzymes by their involvement in assorted pathways
based on their functions and the organelles that house these reactions. Fox and Stover created four
distinct functional categories for these enzymes which include (i) one carbon generating enzymes,
(ii) THF interconverting enzymes, (iii) THF-dependent biosynthetic enzymes and (iv) the noncatalytic THF binding proteins.17 These enzymes can be further distinguished based on the
organelle in which they performed their specialized metabolic function. In general, the metabolic
products formed in these reactions are not exchanged with other cellular compartments, which
offers an explanation for the seemingly redundant existence of metabolic enzymes (or isozymes)
in the mitochondria, cytoplasm and the nucleus (Figure 1.5).8
There are a number of enzymes involved in the folate-dependent one-carbon metabolic
cycle. In this cycle, folate is used as a very versatile carrier molecule that can transfer activated
one-carbon units of varying oxidation states from one metabolic reaction to the other. These
enzymes may be present in multiple isoforms with very specific roles that are determined by where
they are compartmentalized and when they are expressed; this may vary with the stage of cell
cycle, cell type and most interestingly, in normal versus cancer cells.17,34 The first enzyme that
the naturally occurring folylpolyglutamate, 5-methyl THF, encounters is the cytoplasmic enzyme
methionine synthase (MS). This enzyme is characterized as a THF biosynthetic enzyme and acts
to transfer the methyl group from 5-methyl THF to participate in the remethylation of
homocysteine and the production of methionine. The latter, upon adenylation, becomes the
universal methyl donor, S-adenosylmethionine (SAM), which is responsible for a number of
cellular methylation events. In addition, this reaction also leads to the regeneration of the THF
cofactor, which can now act as a carrier molecule and serve as a substrate for cytoplasmic serine
hydroxymethyltransferase (SHMT). Cytoplasmic SHMT is a one-carbon generating enzyme that
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participates in the pyridoxal-5 phosphate- (PLP also known as vitamin B6) dependent reversible
conversion of serine to glycine.17,39 In this reaction, the C3 of serine is transferred to THF, forming
N5,N10 methylene THF and the resulting glycine product. 19,23 SHMT is appropriately regarded as
the most critical enzyme in folate metabolism due to the importance of the metabolic product it
yields, N5, N10-methylene THF, which serves as a substrate for multiple enzymes in this pathway.
In the cell, SHMT exists as three isoforms with some overlapping functions. The function
of each isoform appears to be dictated by the organelle that houses the enzyme. However, one
feature that is common among the isoforms is the irreversible inhibition by 5-formyl THF
(leucovorin) which acts to negatively regulate all isoforms, albeit to varying degrees.40 Studies
have shown that the primary role for the cytoplasmic isoform, SHMT1, is to direct the cycle in the
direction of glycine, resulting in the production of N5, N10-methylene THF for the production of
thymidylate or thymidine monophosphate.41-43 The monophosphate is later converted into the triphosphate form that serves to support DNA replication and repair as the pyrimidine nucleotide,
thymidine triphosphate (dTTP).

However, depending on the cellular environment, N5,N10-

methylene THF can be converted into other metabolic products that could lead either to the
remethylation of homocysteine or the de novo production of purine nucleotides.
Limiting concentrations of N5,N10-methylene THF, in conjunction with the demand for this
folate derivative in feeding multiple outputs in the metabolic pathways, creates competition and a
requirement for intricate feedback regulation to prevent accumulation of metabolic products. The
interconnectedness of three metabolic cycles is clearly exemplified by the fate of N5,N10methylene THF and the importance of the SHMT enzyme. As previously mentioned, the folate
derivative 5-methyl THF serves as the immediate substrate leading to the remethylation of
homocysteine, resulting in methionine and consequently SAM production.

Elevated SAM
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concentrations can lead to the inhibition of 5,10-methylene tetrahydrofolate reductase (MTHR),
the enzyme responsible for the reduction of N5,N10-methylene THF to 5-methyl THF.8,17,19 In
doing so, SAM regulates the folate cycle to allow cellular provisions for de novo nucleotide
biosynthesis while maintaining homeostasis for the methionine cycle.42 Cytoplasmic SHMT has
also been implicated in the regulation of the flux of this pathway that preferentially supplies N5,
N10-methylene THF to TS by two proposed mechanisms: (1) acting as a folate binding protein and
sequestering 5-methyl THF from the enzymatic activity of MS; and, (2) as the SHMT reaction is
reversible, it can act to deplete the N5,N10-methylene THF pool to synthesize serine with the use
of glycine, therefore preventing its conversion to 5-methyl THF by MTHR.17,42
Additional validation of the important role of cytoplasmic SHMT role in the production of
thymidylate is suggested by the binding of 5-formyl THF to cytosolic SHMT1. Studies have
suggested that this binding acts a regulatory switch to drive the pathway towards thymidylate
synthesis instead of the remethylation of homocysteine.40,42 The mitochondrial SHMT2 isoform
is believed to be involved in the conversion of serine to glycine and is ubiquitously expressed
(thought to be responsible for the majority of the glycine content in cells). The cytoplasmic
isoform is predominately found in the kidney and liver where it is not as active in the serine to
glycine conversion. It facilitates the reversible interconversion of serine and glycine while forming
5,10 methylene THF.44
Serving as one of the most critical components of this pathway, 5, 10-methylene THF is
principally involved in the methylation of dUMP to dTMP in thymidylate formation catalyzed by
TS.26 Dihydrofolate is the by-product of this reaction, which is converted to THF by dihydrofolate
reductase (DHFR). THF can be metabolized to promote an additional revolution in this cycle.
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Synthetic folic acid supplements also act to generate THF when reduced to the di- then
tetrahydrofolate cofactor form by DHFR.
In addition to participating in thymidylate formation, 5, 10-methylene THF can be reduced
to 5-methylTHF by MTHR. THF can be converted into 10-formyl THF by mitochondria-derived
formate and cytosolic ATP. This enzyme is also responsible for the irreversible conversion of 5,
10-methenyl THF to 5- formyl-THF.
Both the mitochondrial isozyme SHMT2, and cytoplasmic enzyme SHMT1 play a critical
roles in one-carbon metabolism through the production of active one-carbon units and the
production of serine, glycine and formate that can also serve as carbon donors for other reactions.
Interestingly, compartmentalization of these enzymes determines the fate of the newly formed
product, 5,10-methyleneTHF (Figure 1.5).20 Radioactive isotope tracing experiments provided
evidence that cytoplasmic SHMT (SHMT1) produces this substrate for the transmethylation of
dUMP, performed by the cytoplasmic and nuclear TS.45
Both in vivo and in vitro studies have identified the SHMT conversion of THF to 5, 10methylene THF as the rate-limiting step in thymidylate synthesis. In vitro studies with SHMT -/null mice show a near 75% reduction in TS activity in isolated nuclei.46,47 The abundance of
NADPH/NADP+ supports a reductive cytoplasmic space that makes the conversion of 5,10methylene THF to 10-formylTHF highly unlikely; therefore the cytoplasmic supply of 5,10methylene THF does not support the purine biosynthetic pathway.17 Rather, as demonstrated by
previous observations of SHMT1, the cytoplasmic isozyme is principally involved in the
production of 5,10-methylene THF to support thymidylate synthesis.42 There is research that
demonstrates the unique role of mitochondrial SHMT2 function, which is distinguishable from its
cytoplasmic counter parts, SHMT1 and SHMT2α.17,40
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Mitochodrial folate metabolism
Conjugated folates cannot be transported into the mitochondria, as polyglutamylated
species are not substrates for the mitochondrial folate transporter (MFT), solute carrier family
member SLC25A32.19,20 However, the shared affinity for monoglutamylated folate forms between
MFT and folypolyglutamate synthase creates competition among these two proteins in the
cytoplasm.19 Monoglutamate forms of folates that successfully enter the mitochondria generate a
distinct folate pool that is maintained within the organelle.20 The mitochondria serves as an
important source of cytoplasmic carbon, glycine and formate.48 Mitochondrial formate is a product
of serine, glycine, dimethylglycine, sarcosine and choline catabolism.8 SHMT2 provides carbon,
glycine and formate to participate in cytoplasmic biosynthetic reactions offered by the
mitochondrial metabolism of serine.8 The glycine autotrophic CHO cell line clearly illustrates the
independence of function of the cytoplasmic and mitochondrial SHMT isozymes.19
Additional sources of 5, 10-methylene THF include the glycine cleavage system, which is
a multi-enzyme system that participates in the oxidation of glycine into 5, 10-methylene THF, CO2
and ammonia.8 This system is thought to produce 40% of glycine flux, with the one carbon units
produced from this system contributing to purine and thymidylate biosyntheses that occur in the
cytoplasm.8
De novo purine biosythesis
The de novo purine nucleotide biosynthetic pathway is a multi-step enzymatic process that
yields IMP from the initial starting product phosphoribosyl pyrophosphate (PRPP). The numbered
reactions shown in Figure 1.3 are catalyzed by the following monofunctional enzymes: 1,
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glutamine phosphoribosylpyrophosphate amidotransferase (GPAT); 4, formylglycinamide
ribonucleotide synthase (FGAM synthetase); and 8, adenylosuccinate lyase (ASL). Reactions 2,
3 and 5 are catalyzed by the trifunctional glycinamide ribonucleotide (GAR) formyltransferase
(GARFTase) which contains GAR synthase (GARS; reaction 2), GAR formyltransferase
(GARFTase; reaction 3) and 5-aminoimidazole ribonucleotide synthase (AIRS; reaction 5)
activities. Reactions 6 and 7 are catalyzed by the bifunctional phosphoribosylaminoimidazole
carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzyme,
which contains carboxyaminoimidazole ribonucleotide synthase (CAIRS; reaction 6) and 5aminoimidazole-4-(N-succinylocarboxamide ribonucleotide synthase (SAICARS; reaction 7)
activities. Reactions 9 and 10 are catalyzed by a bifunctional enzyme, 5-aminoimidazole-4carboxamide

(AICA)

ribonucleotide

(AICAR)

formyltransferase

(AICARFTase)/IMP

cyclohydrolase (ATIC) that catalyzes the last two steps in the pathway for de novo synthesis of
IMP. Folate-dependent reactions (reactions 3 and 9) in which 10-formyl THF serves as the onecarbon donor are catalyzed by GARFTase and AICARFTase.

AICA and AICAR can be

metabolized to AICAR monophosphate (ZMP) by either adenine phosphoribosyl transferase
(APRT) or adenosine kinase (AK), thus circumventing the reaction catalyzed by GARFTase. The
activation of AMPK that results in inhibition of mTOR is also depicted.
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Reprinted with the permission of Mitchell-Ryan et al. (2013) Copyright. J Med Chem
Figure 1.3: De novo purine biosynthesis. The activated ribose PRPP, the phosphorylated product
of the pentose phosphate pathway, is systematically converted into the purine precursor IMP in a
10 step process. Folate-dependent steps 3 and 9 are initiated by the enzymes GARFTase and
AICARFTase, respectively. In addition to the de novo production of purine nucleotides, this
pathway also provides metabolic intermediates (i.e., AICAR (ZMP)) that can activate signal
transduction pathways that are responsive to cellular energetics which function to modulate cell
survival via AMPK activation and mTOR inhibition.
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GARFTase and AICARFTase are two cytoplasmic enzymes involved in de novo purine
synthesis. These folate-dependent enzymes work to generate inosine monophosphate (IMP), a
purine precursor that can be further metabolized to guanosine and adenosine nucleotides. There
are two pathways responsible for intracellular purines, the de novo purine pathway and salvage
pathways (Figures 1.3 and 1.4). Most often, normal cells that possess intact machinery for the
salvage pathway will undergo this energy efficient method that uses preformed bases from
degraded and metabolized purines that are recycled into nucleotides for the use in DNA
synthesis.49 The process of cellular transformation introduces chromosomal abnormalities that
include deletions in chromosomal segments that house tumor suppressor genes. One common
deletion involves chromosome 9, and is reported to include the chromosome 9p21 locus of
multifunctional tumors suppressors, p14ink4a, p15ink4b and p16ARF.50,51 Methylthioadenosine
phosphorylase (MTAP), an essential enzyme in the purine salvage pathway that is often co-deleted
with other well-established aforementioned tumor suppressors located on chromosome 9.46,47
Tumors that harbor this deletion lack the capacity to use this purine salvage pathway as a source
of purines and are heavily dependent upon the de novo purine biosynthetic pathway to support the
high demand for purine nucleotides and carbon backbones in aberrant cell division.46,47
There is some debate over the folate metabolite(s) that acts as a coenzyme for purine
biosynthetic reactions. Earlier studies proposed 10-formyl THF as the sole cofactor associated
with the conversion of GAR and AICAR to their respective formylated species formyl glycinamide
ribonucleotide (FGAR) and formyl 5-aminoimidazole-4-carboxamide ribonucleotide of
(FAICAR), driven by GARFTase and AICARFTase.8,17 However, more recent studies suggest
that 10-formyl dihydrofolate not only plays a part in the activation of these enzymes but is the
preferred substrate for AICARFTase.52,53
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Adapted open access figure with the permission of Lubin M, Lubin A (2009) Selective Killing of
Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy. PLoS ONE 4(5):
e5735
Figure 1.4: The purine salvage pathway and cellular products. MTAP is an essential enzyme
in the purine salvage pathway, producing both 5’-deoxymethylthioribose-1-phosphate (MTR-1-P)
and the adenine free base. Through APRT, adenine can be converted into AMP and later into ATP
following phosphorylation events, thereby aiding in cellular energetics. Deoxyribose AMP
(dAMP) can be converted into the purine nucleotide adenosine, which can incorporated into DNA
during replication and DNA damage repair. Through a multistep process, MTR-1-P is converted
into Methionine, that can go on to assist in protein synthesis. The loss of MTAP would leave the
cell dependent upon de novo purine synthesis for adenosine nucleotides, and therefore DNA
replication.
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Nuclear folate metabolism
An increasing number of studies have described a type of folate metabolism that occurs in
the nucleus. This is thought to arise from the nuclear translocation of SHMT2α (which has a
redundant role in both the cytoplasm and the nucleus), TS and DHFR, which form a multi-enzyme
complex to facilitate nuclear thymidylate synthesis.47

The purported significance of this

physiological event is to maintain genomic integrity in DNA replication and repair (as this has
been cited to occur during S, G2/M and during damage to DNA from UV exposure), in addition
to preventing the mis-incorporation of uracil.45,47 This also holds particular significance in the
prevention of uracil accumulation, which also plays a part in compromising genomic integrity.45
Further, in vitro studies have substantiated these observations by indicating that nuclear membrane
disruption (via sonication) resulted in nuclei that failed to possess de novo TS activity.45
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Adapted with permission of Fox et al.17 Copyright (2008) Vitamins and Hormones. Ch. 1
Figure 1.5: The compartmentalization of folate metabolism. Folate metabolism can occur in
three compartments with the cell, the mitochondria, the nucleus and the cytoplasm. Not much is
known about nuclear folate metabolism, however, it is thought to play an important role in
thymidylate synthesis. Folate pools in the cytoplasm and the mitochondrial are not
interchangeable. The mitochondrial formate combines with cytoplasmic THF to produce the folate
cofactor essential for de novo purine synthesis.
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1.3 Folate tissue absorption
Mammals must acquire preformed folates from the diet due to an inability to synthesize
these water–soluble vitamins de novo. Dark green leafy vegetables and select fruits are notable
high sources of the vitamin. Intracellular accumulation of folates is predominately performed by
transmembrane carriers/transporters and receptors. Tissue accumulation of folate is dictated by
the expression of transporters/carriers that permit the influx of folates, polyglutamylation at the γ
glutamate on the carboxyl end of the parent molecule and expression or ability for exporter proteins
to bind folate and contribute to their efflux from cells.
The mechanisms of folate transport have been evolutionary conserved over many millions
of years. The existence of the two solute carrier (SLC) family members that participate in folate
transport, SLC19A1 (reduced folate carrier or RFC) and SLC46A1 (proton coupled folate
transporter or PCFT) date back to the Vendian period (approximately 523-543 million years ago).15
Genes of both transporters have been identified in Pseudocoelomata, more specifically
C.elegans.15

Folate receptor genes evolved much later and made their first appearance in

chordates.15 Salbaum and colleagues speculate that folate receptors (FRs), with their superior
binding affinities, evolved to ensure genomic stability and to preserve DNA methylation patterns
even when folate supplies were limited.15 Folate availability is an important factor in modulating
the expression levels for each of the three proteins. A number of studies have confirmed that low
concentrations of folates lead to increased expression of intestinal RFC and PFCT.54-57 Much like
RFC and PCFT, FR alpha mRNA transcripts and protein expression is increased under folatedeficient conditions.58-63 Cancer is one of many disease states that can result in a decrease in serum
folate levels due to the increased demand for folate cofactors to participate in DNA replication for
rapidly dividing cells.64 Interestingly, patients with FRα positive tumors, like ovarian cancer, have
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increased levels of FRα protein in their serum.65-67 Due to this elevation, serum FRα levels have
been considered as a plausible biomarker to detect epithelial ovarian cancer.65,66
The Reduced Folate Carrier (RFC;SLC19A1)
The RFC, as its name suggests, is a facilitative transmembrane transporter with a very high
affinity for reduced folates (Km: 1-3µM), e.g 5-methyl-THF.25 The RFC protein is comprised of
591 amino acids and has a molecular mass of approximately 65 kDa (Figure 1.6).25,68 Due to
pronounced glycosylation at residue Asn 58, the molecular weight of the modified protein is
~85kDa, a ~20 kDa difference from the original molecular weight of ~65 kDa.25,69 The human
RFC gene is located on chromosome 21q22.2 and is reported to be regulated by a host of regulatory
proteins and transcriptional start sites.70 The very complex transcriptional regulation of RFC is
carried out by six non-coding exons with multiple promoters and with the aid of multiple
transcription factors from various families.71,72 RFC has been described by Whetstine and
colleagues as a ubiquitously, but differentially expressed protein.73 In this study they speculated
that the differential expression and the utilization of multiple promoters and transcription factors
could be the product of varying folate demands in various tissues.73 The expansive expression of
this protein, along with its ability to act as a “high capacity” carrier of reduced folates has led to
the belief that RFC is responsible for the bulk influx of reduced folates into mammalian cells,
thereby having the greatest impact on the intracellular folate pools.69,74 As the major transporter
of reduced folate derivatives, it is conceivable that both normal and malignant tissues would find
expression of this protein advantageous for successful DNA replication and for the preservation
of genomic integrity. In fact, quantitative real time PCR (RT-PCR) and multiple methods of
protein detection have validated RFC expression in various human tumors and tissues. Human
RFC mRNA transcripts have been identified in cells from various origins including the central

23

nervous, leukocytes, liver, placenta and the intestine.73,75 The presence of RFC expression in
normal tissues has also implicated the protein as the source of dose-limiting toxicities seen in
patients treated with antifolates that are accumulated into normal tissues through this mechanism.69
The bidirectional transport of RFC is driven by the extrusion of organic phosphate which
allows for the exchangeable influx of reduced folate derivatives and a select number of antifolates
that are recognized by this protein.25,69 While the exact mechanism of exchange is not fully
understood, some speculate that it involves a trans-stimulation phenomenon whereby the
movement of a molecule in one direction enhances or “stimulates” the movement of another
molecule in the opposite direction.76,77 Optimal transport generally occurs at a neutral pH (7.4),
although some studies have demonstrated residual RFC transport at a low pH.78,79 Interestingly,
prior to the discovery of PCFT, RFC was thought to be responsible for low pH folate transport in
the intestine where the protein is expressed.80 However, more recent experiments have confirmed
that RFC transport of leucovorin, a reduced folate derivative, was severely impaired at pH 6.5.69,81
While it has been demonstrated that RFC plays little to no role in the intestinal absorption of dietary
folates, folate depletion increases the intestinal expression of RFC and the role of RFC in this
context has yet to be determined.26,55,56 Studies suggest that RFC does not play a major role in the
tissue absorption and or transport of folic acid (Km~200µM) which may partly explain the reduced
transport efficiency seen with novel antifolates that closely resemble the chemical structure of folic
acid.25,75
The principal route of cellular entry for many “classical” antifolates (i.e., AMT,
methotrexate (MTX) and pemetrexed (PMX)) is through RFC. The pharmacological impact of
RFC expression on the activity of a number of antifolates has been extensively studied. Many of
these studies have demonstrated that the functional loss of RFC modulates drug sensitivity.74,82 In
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the case where drug influx is completely RFC-dependent, cells exhibit resistance. Alternatively
and contrary to what one may expect, the loss of RFC increases drug sensitivity with agents that
can undergo non-RFC-mediated cell transport, thought to be a consequence of a contracted
intracellular folate pool, which diminishes competing substrates for targeted enzymes, therefore
increasing drug potency.82-84
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Reprinted with permission of Hou, et al. 85 Copyright (2006) American Society for Biochemistry
and Molecular Biology.
Figure 1.6: Predicted topology map of human reduced folate carrier (hRFC). hRFC is an
integral membrane protein consisting of 12 transmembrane domains and both intracellular and
extracellular loops. The diagram attempts to designate specific amino acid sequences within the
cell membrane, as well as those exposed to the extracellular and cytosolic space. Topology
modeling allows for a greater understanding of how hRFC functions and encourages the generation
of hypotheses surrounding the identification of critical amino acid residues involved in the activity
of the protein.
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The Proton-Coupled Folate Transporter (PCFT; SLC46A1)
The proton couple folate transporter (PCFT) is the most recently identified of the
predominant mechanisms of folate transport.86 Prior to receiving its current designation as a folate
uptake mechanism, it was originally named the heme transporter protein-1, which describes its
ability to effectively transport heme in the intestine (Km:125µM).25,87 The dietary acquisition of
folates begins in the acidic micro-environment of the duodenum and upper jejunum of the
intestines.88 The existence of a low pH folate transporter became evident as accumulating data
ruled out RFC despite its expression in the intestinal brush boarder membrane. More specifically,
early experiments using a RFC-null HeLa model validated the existence of a non-RFC low pH
transport mechanism that was later determined to be PCFT.89 The cloning of PCFT by Qui et al
formally identified PCFT as the low-pH folate transporter.86 This soon led to structural and
biological studies to obtain more information about the protein and how it participates in folate
homeostasis and more importantly what role if any it plays on the pharmacological activity of
antifolates in clinical use.
Like RFC, PCFT is an integral membrane protein that participates in the facilitative
transport of (anti)folates and is also a member of the major facilitator super family (MFS).
However the transport profile and mechanism of transport is distinct from that of RFC.73 The
unidirectional transport of folates has been described as electrogenic and proton driven and occurs
optimally at a low pH (5.5), hence the naming “proton coupled”.73 The charge carried by the
proton creates an electrochemical gradient which classifies this proton driven mechanism as
electrogenic.80,90
The PCFT chromosomal location is 17q11.2 which encodes a 55 kDa protein made up of
459 amino acids (Figure 1.7).25,91,92 PCFT is encoded from 5 exons with a minimal transcriptional
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regulatory region located -42 and +96 bases from the transcriptional start site.75,91-93. Transcription
of this protein is thought to be governed by a number of factors. Kruppel like factor -4 (KLF-4),
hepatocyte nuclear factor (HNF-1) and nuclear respiratory factor -1 (NRF-1) have all been reported
to enhance PCFT promoter activity resulting in an increase in PCFT transcripts. 94,95 Vitamin D
was also shown to increase PCFT expression via the transactivation of the PCFT promoter by the
vitamin D receptor (VDR) when heterodimerized with retinoid X receptor –α (RXRα).96 Promoter
hypermethylation results in decreased transcriptional activity and therefore gene product.93 While
little is known about the intrinsic transcriptional regulation of PCFT, studies have shown that
xenobiotics, more specifically, proton pump inhibitors, can decrease intestinal PCFT expression
in patients administered this type of therapy.97
Compared to RFC, PCFT has restricted tissue expression that is limited to the duodenum,
jejunum, liver, kidneys, and choroid plexus and comparably much lower expression in the bone
marrow and colon.88 A wide range of malignant cells express PCFT, including but not limited to
tumors of the colon/rectum, lungs, liver and ovaries.98 The expression of PCFT may be especially
advantageous in tumors with high glycolytic activity or what had been described as “The Warburg
effect”, creating a proton-rich acidic microenvironment.

In theory, the creation of such a

microclimate would increase the activity of PCFT and provide a context in which RFC activity is
reduced. This very observation is the basis of PCFT-targeted anti-tumor therapy.75 A better
understanding of the transcriptional regulation of PCFT will undoubtedly result in novel
approaches and creative strategies to improve drug efficacy in PCFT-expressing tumors.
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B.

Adapted with the permission of Shin, et al. 99Copyright (2012) The American Physiological
Society and Unal, et al. 100Copyright (2009) American Journal of Physiology. Cell Physiology
Figure 1.7: Homology model and predicted membrane topology for hPCFT. (A) The
cartooned homology model of hPCFT (generated from the bacterial glycerol-6-phosphate
transporter) demonstrates a side view of the protein. Featured in this model the two residues (Ala
335 (red ) and Gly 338 (yellow) that were found to be mutated in human folate malabsorption
syndrome, which believed to play an important role in protein stability. In addition, the spatial
arrangement of transmembrane domains (TMD) 9 and 10 and their proximity to the transport
channel are also shown. Much like the predicated membrane topology (B), loops that are believed
to reside in the intracellular or extracellular space are shown above. The topology model
highlights conserved (black) and partially conserved residues (arrows) within the TMDS.
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Folate Receptor alpha (FRα)
FRs are an extensively studied family of proteins that are recognized for their role in
embryonic and fetal development where they act as an essential mechanism of folate transport,
supporting rapid cell division during gestation. FRs, also known as folate binding proteins (FBP
or folbp for murine homologs) were first identified in bovine milk in 1972.101,102 Since the
discovery of these high affinity/low capacity folate binding proteins, four isoforms and pseudogenes have been identified. While each isoform shares some sequence homology (70-80%), they
each possess distinct structures, patterns of tissue expression (with some overlap), binding affinity
and stereospecificities.103,104 Collectively, FR’s have the highest affinities toward folic acid,
physiological reduced folates and formylated THF (5-formylTHF) compared to PCFT and RFC.25
These features allow FRs to successfully engage in cellular uptake when folate concentrations are
low. These genes are all a part of a larger superfamily that includes the riboflavin binding protein
and the retinbindin, a retinal binding protein.103 Prior to the solving of the crystal structure of FRα,
homology modeling using bovine riboflavin binding protein was employed to elucidate or to gather
more insight on the structural characteristics of this protein and possibly other identified isoforms
due to known similarities of each protein.105
FR genes, Folr 1-4, are localized to chromosome 11q13.3-14 and are responsible for the
transcription for FRα, β, γ/γ’ and δ.62,103,104 Of the four isoforms, FRδ is the most recently
discovered. While the mouse ortholog, folrbp3, is expressed in the mouse thymus and spleen and
is thought to play a role in the proliferation of immune cells, expression of this isoform has not
been detected in human adult or fetal cells.104 The failure to detect FRδ in human tissues has been
thought to arise from the temporal/spatial regulation and expression of the protein.104 Others
suggest that like FR pseudogene1 (Folr1p) identified by Raggoussis et al., the delta isoform is a
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pseudogene in the human genome.104,106 Due to an elusive pattern of expression in human tissues,
the capacity of this isoform to bind folate is undetermined, as well as its putative role in folate
metabolism and perhaps cell signaling.
Much like the delta isoform, little is known about FRγ, when compared to the more
prominent and widely studied β and α isoforms. Unlike FRδ, the gamma isoform has been
identified in human tissue. The protein was first discovered in 1993 and was identified as an
overexpressed high affinity folate binding protein in chronic myelogenous leukemia (CML) and
acute myelogenous leukemia (AML) patient samples.107 Since the discovery of the γ isoform, it
has been identified in normal hematopoetic cells, bone marrow, spleen and thymus.103 Of the three
functional forms of FR expressed in human tissues, FRγ is to date, the only identified polymorphic
isoform of this family. A genetic polymorphism results in a mutation that codes for a premature
stop codon leading to the translation of a truncated non-functional protein, FRγ’.108 Despite
multiple N-glycosylation sites (3) which are shared among all isoforms and are thought to
contribute to the cell surface expression of the protein, there is an additional anomaly that
distinguishes FRγ from its counterparts- this protein is constitutively secreted due to a lack a
hydrophobic amino acid sequence that serves as a signal for glycosylphosphatidylinositol (GPI)
modification that anchors the protein to the cell surface.103,109
FRs are known to exist in membrane bound and soluble states. Membrane bound receptors
(α and β) are anchored to the membrane by glycolipids known as GPI anchors.103,110 This GPI
modification is signaled by the hydrophobic carboxyl terminal segments in the α and β isoforms
which allow for a post-translational transamidase reaction, resulting in the cleavage of the present
C-terminus while creating an amide linkage to the GPI and a newly formed C-terminus.103,110
Soluble folate binding proteins (sFBP) arise from the membrane-bound forms that undergo well-
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defined cleavage events. They are generally present in extracellular fluids, which include milk,
cord blood, urine, and cerebrospinal and amniotic fluids.103 The soluble FR α isoforms are thought
to be the result of (1.) the phospholipase cleavage of the GPI anchor or (2.) proteolysis by a Mg+2
dependent protease.103 These mechanisms are thought to be responsible for soluble α isoforms
detected in KB nasopharyngeal carcinoma cells in culture and those detected from placental cells.
In contrast, the soluble β isoform is the product of two independent pathways that either result in
GPI anchor attachment or secretion.103 All soluble forms of the protein have been shown to bind
and stabilize folates; therefore these soluble proteins may have a functional role in normal
physiology.103 For instance, the sFBP in milk are thought to play a role in the intestinal absorption
of folates.103 These soluble proteins may also serve a diagnostic purpose in detecting disease as
many pathological conditions, including cancer, results in the aberrant shedding of these
membrane proteins into the circulation where they are not generally detected in healthy
individuals.103,111
The FR β has increasingly become the subject of interest due to its role in a number of
human pathologies, most notably cancer and inflammation.103,112-116 The expression of this
isoform is confined to hematopoietic cells of the myelomonocytic lineage and the protein is
routinely used as a differentiation marker in normal hematopoiesis.103 Protein expression extends
to the placenta and to mature neutrophils with elevated expression seen in activated blood
monocytes and the expression status remains consistent during their transformation to
macrophages.103 Macrophages are known to play a critical role in the initiation, maintenance and
resolution of the inflammatory process.113 Rheumatoid arthritis (RA) is a disease characterized by
the infiltration of lymphocytes and macrophages to synovial joints, causing proliferation of local
fibroblasts and severe joint damage. Activated macrophages in synovial tissues from RA patients
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were shown to have significant expression of the β isoform.116 The selective expression of FR β
on this population of macrophages makes this isoform an excellent target for therapies specific to
this protein isoform. Presently, the antifolate MTX is the preferred treatment option in patients
suffering from RA.117 However, MTX substrate promiscuity among other mechanisms of folate
transport has created a demand for novel therapeutics that have selective uptake by FR β.117-119
These therapeutics may not only prove useful in the treatment in RA, but they may also show
efficacy in FR β-expressing malignancies such as leukemia (CML and AML). Tumor-associated
macrophages (TAM’s), which also express FRβ, have been implicated in the initiation and
progression of a number of malignancies.120-122 Folate-based therapies targeted to FR β may
extend the survival of patients diagnosed with difficult to treat tumors like pancreatic cancer which
are reported to have significant TAM infiltration.123,124 An additional and perhaps more practical
application in exploiting the population of TAMs in cancer is the use of fluorescent conjugates
linked to FR β, which may serve as an optical tool that can aid in detection of relapse (in the case
of hematopoietic disease), primary tumors and their metastasis.122
FRα is, by far, the most extensively studied of the four FR isoforms. While this receptor
has been well documented as a mechanism of folate transport, additional physiological roles of
FRα continue to be the subject of many ongoing studies. Much intrigue surrounds the functional
role of FRα especially when co-expressed with other high capacity folate uptake mechanisms such
as PCFT or RFC, which has led to speculation on alternative roles for this receptor. Undoubtedly,
FRα has a clear role in the reabsorption of folates from kidney proximal tubules and in embryonic
development, including the development of the neural tube and transplacental folate transport from
mother to fetus. What remains unclear is the utility of this receptor when expressed in other
epithelial tissues with limited or no access to circulating folates. One popular line of reasoning
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suggests that FRα, when expressed in tissues with limited access to circulation, acts as a folate
scavenger and participates in the transcellular transport of folates, as described in the transport of
folates across the retinal pigment epithelia, the luminal uterine epithelia during pregnancy and in
lung epithelia to prevent bacterial growth.125,126 It has been proposed that FRα, like other GPI
anchored proteins clustered by lipid rafts, participates in signal transduction pathways that are
involved in regulation, survival and growth.127,128 More studies are required to determine and
validate the exact signaling pathways that are involved with ligand-bound FRα.
There are a number of disorders associated with mutations or the functional loss of FRα.
The homocysteinylation of FRα, a consequence of excess/elevated homocysteine, may lead to the
development of FRα autoantibodies which are thought to contribute a significant decrease in folate
uptake, resulting in defects in the developing embryo.129,130 Such deficiencies that arise from
deleted, dysfunctional or blocked FRα have been linked to NTDs, orofacial cleft, congenital heart
defects, autism spectrum disorders and cerebral folate deficiency (CFD).130-132 CFD is thought to
arise from the presence of FRα autoantibodies or a loss of function mutation in the folr1 gene,
causing a neurological syndrome that presents in children as young as 4 months with cognitive and
neuromuscular deficits.133,134 Studies have shown that maternal FR autoantibody concentrations
are linked to NTDs, further highlighting the important role of FRα in embryonic
development.130,131,135 An incomplete understanding of FRα’s role in signal transduction makes it
difficult to delineate if folate deficiency or a disruption in signal transduction pathways play a
causal role in the development of such malformations. More work in this area may lead to a greater
understanding of the tissue distribution of this protein and the global importance of its expression,
in addition its acknowledged role in folate metabolism.
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As previously mentioned, FRα has a unique and distinct pattern of tissue expression. In
adult tissues, FRα is confined to the apical surface (luminal) of polarized (non-transformed) cells
of epithelial origin, including the choroid plexus, proximal renal tubules, fallopian tubes, uterus,
epididymus, acinar cells of the breast, submandibular salivary and bronchial glands, type 1 and 2
pnuemocytes in the lung and placental trophoblasts.103 The only known basolateral surface
expression of this protein has been identified in the epithelia of retinal pigment cells.103 The
luminal expression of FRα, by virtue of its physical location, makes this receptor inaccessible to
circulating folates in the blood.136-138 The role that FRα plays in the reabsorption of folates from
the kidneys creates an opportunity for renal FR to encounter serum folates.103 Interestingly, it has
been reported that glomerular filtration allows for the separation of low molecular weight FRαtargeted drugs that are transcytosed, thereby preventing renal accumulation of cytotoxic agents
and circumventing neurotoxicity.136
Many epithelial based tumors also express FRα, however, ovarian and endometrial cancers
are among the most recognized partly due to their consistent and elevated expression of the protein.
One classic feature of the transformed cell is the absence of cellular organization (loss of polarity)
and a disruption of cellular architecture. These structural changes that occur during tumorigenesis
lead to the altered spatial orientation of the receptor such that it is expressed on the basolateral
surface. The newly acquired basolateral surface expression of the receptor on tumors permits the
sequestration of circulating (anti)folates due to a change in orientation that leads to accessibility.
We argue that this feature, in addition to the very narrow and restricted tissue expression exhibited
on normal tissues, makes FRα a rational and attractive target for drug delivery to promote the
selective killing of FRα-positive tumors.
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There are many theories surrounding the elevated expression of FRα in select epithelial
malignancies. Many of these encouraged thorough investigations of the regulation of folr1 gene
and gene products in both normal and transformed cells. The complex regulation of FR genes is
governed by a variety of factors which include serum folate concentrations, nuclear receptors and
their respective ligands, and post transcriptional/translational modifications.

Although FR

isoforms share significant sequence homology, the organization of the gene, the use of alternative
promoters and alternative splicing distinguishes each isoform from the other while also accounting
for the differences observed in tissue distribution. 96
The folr1 gene has a reported length between 6.7

139

and 7.5 kb 140 and is composed of 7

exons and 6 introns that encodes a 257 residue polypeptide and a 38-42 kDa protein.141,142
Multiple transcripts of folr1 have been identified and appear to be the product the use of alternative
promoters, as well as alternative splicing that occurs at exons1-4.141-143 The promoters responsible
for the diverse FRα mRNAs are TATA-less and designated P1 and P4, located upstream of exons
1 and exon 4, respectively (Figure 1.8).103,140 Although they produce divergent transcripts, the
protein product derived from each promoter is identical.142 The regulation of transcription, the
efficiency of translation and the length and sequence of the resulting transcripts are where these
two promoters diverge.82,111,142 Despite these differences, the open reading frame (ORF), 3’
untranslated region (UTR) and mRNA stabilities are the same for transcripts derived from both
promoters in FRα-expressing cells.142 The P1 and P4 promoters are reported to be under tissuespecific regulation which is thought to account for the abundance of specific transcripts in specific
tissues. 82,142
Relative to P4, not much is known P1 promoter, but this promoter is understood to exhibit
functional and structural differences from the P4 promoter.141 Transcripts produced by the P1
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promoter have been identified in the normal human kidney, the testis and the cerebellum of the
brain.103,141 The multiple initiation sites combined with the alternative splicing of upstream exons
results in heterogeneity of the 5’ UTR in the transcripts generated and explains the varying lengths
and sequences of the 5’ UTR among the transcripts.142 The regulation of the P1 promoter in certain
ovarian cancer cells differs from that which is seen in normal human cells. Bagnoli and colleagues
described an inverse relationship between caveolin-1 protein, known to negatively regulate
intermediates in signal transduction involved with cell proliferation, and FRα expression in human
ovarian cancer cells.139,144 The result of their efforts determined that caveolin-1 negatively
regulated FRα expression through repression of the P1 promoter.144 Additional studies examining
P1 regulation in ovarian carcinomas concluded that the promoter was under the control of a variant
hepatocyte nuclear protein that enhanced promoter activity via the interaction of a DNA-binding
site located in the untranslated region of exon1.139 Exon 1 is believed to include the elements
required for optimal transcriptional activity for the P1-derived FRα transcript in ovarian cancer
cells.139 For reasons not fully understood, P1 transcripts display a lower rate of translation
efficiency when compared transcripts generated from the P4 promoter.142

Whether or not

translation efficiency corresponds to surface expression density, is yet to be determined.
Additional research is required to validate if similar factors modulate P1 promoter activity in
normal cells and to determine if there is a direct relationship between promoter activity and overall
protein expression.
A number of FRα expressing cells transcribe FRα under the control of the P4 promoter
including the KB nasopharyngeal carcinoma cells and normal epithelial tissues of the lung,
placenta, salivary gland, uterus breast and stomach.103 This promoter’s activity is influenced by
three GC rich sequences that allow for non-canonical SP1 binding, with each of the three sites
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making a significant contribution to promoter activity.103,143

Multiple sites of potential

transcription factor binding were reported to be contained within this promoter, including sequence
motifs for AP2, E-box and the aforementioned SP1 (Figure 1.8).101,140
mRNA stabilities in FRα-expressing cells have been discussed; irrespective of the
promoter of origin, all transcripts are reported to have similar stabilities.103,140,142 However a novel
nuclear post transcriptional mechanism of FRα regulation has been described. Residing in the
ORF is a discrete 60 base pair mRNA element that is reported to control the stability of FRα
mRNA.140 This structure ultimately results in the selective nuclear degradation of FRα transcripts
in FRα null cells and may be responsible for the restricted tissue expression seen with this
protein.140
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Reprinted with the permission of Elnakat and Ratnam
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Figure 1.8: Folate receptors gene organization. Above is a representation of human folate
receptors α, β and γ gene organization. Both the β and γ isoforms are thought to be under the
transcriptional control of a single promoter (indicated here with the letter P) and cis regulatory
elements Sp1 and ets. The alpha isoform shows two promoter regions, P1 and P4. The P4
promoter includes a Sp1 cis regulatory element. The length of the exon and intron present are
featured with numbers above each segment. An examination of the gene organization includes a
visual comparing the genomic similarities of each isoform, while offering an explanation in the
divergence of distribution, expression and function.

39

The inverse relationship between FRα expression levels and serum folate concentrations
has been well documented.59,145-147 Both in vivo and in vitro models have validated the regulation
of this isoform by serum and media folate levels, using both folate-deplete and folate-replete
conditions, the latter including multiple folate metabolites.58,59,148-152 In each instance, restricted
or reduced folate levels accompanied an increase in FRα expression levels, while increasing folate
levels reversed the phenotype resulting in reduced expression levels of the protein. In support of
these studies, an examination of serum folate levels in patients with FRα-positive tumors
recapitulated these experimental results, suggesting that this regulation by folate is a naturally
occurring phenomenon.64,153-156 A consequence of reduced or depleted serum folates is a rise in
homocysteine levels due to inactivity of MS, which is responsible for the conversion of
homocysteine to methionine. Elevated homocysteine levels were shown to encourage or increase
the interaction between the heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) and the ciselement in FRα transcripts, which is believed to result in unregulated translation.157 Other studies
have reported an alteration in the level of mRNA transcripts or amplification of the FR gene.103
The use of antifolates, more specifically MTX, has also been shown to increase FRα
expression.81 MTX resistance is thought to be a result of a number of factors including the
functional loss of RFC or a reduction or silencing of protein expression via gene hypermethylation
or other mechanisms.25,158,159 Experts suggest that MTX resistant cells experience an increase of
FRα expression as an attempt to meet the folate requirements of a malignant cell through the use
of a transport mechanism not affected by drug exposure.81 The exact transcriptional mechanism
is unknown; however, it has been postulated that DHFR inhibition by MTX may mimic the
conditions of folate depletion and may trigger the same regulatory pathways that lead to the
enhancement of FRα expression.81
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Steroid receptors have also been implicated in the regulation of FRα. Activation of
androgen160, glucocorticoid161, and progesterone162 receptors have been associated with increased
transcriptional activity of the P4 FRα promoter and an increase in cell surface FRα protein
expression.

Steroid hormone regulation of the FRα P4 promoter by the progesterone and

glucocorticoid receptors is indirect but it is direct by androgen receptors. In contrast, the estrogen
receptor has been identified to negatively regulate FRα through transcriptional repression.163
Estrogen exerts FRα transcriptional repression by interacting with GC-rich Sp1 binding site(s) of
the P4 promoter and recruiting the co-repressor SMRT which prevents the cluster of transcriptional
machinery.163 This finding was thought to help explain the lack of FRα in ER-positive tumors and
the increased expression in anti-estrogen (tamoxifen) treated tumors.
Many suspect the physiological role of FRα extends beyond the role it plays in folate
transport and metabolism.164,165 Studies have shown that cells that are transfected with FRα
undergo a rapid increase in cellular proliferation and alternatively, cells treated with antibodies,
sense/antisense particles or oligonucelotides directed to this receptor showed a delay in growth
and in some cases reversion of the malignant phenotype.127,164-166 Folate metabolism alone cannot
account for a robust proliferative response but rather alterations in signaling pathways may be
involved. Notch and Hes-1 were both implicated in FRα directed cell growth in alpha T3-1 cells
transfected with FRα.164 In addition to cellular proliferation, FRα has also been linked to cell
motility, resistance to apoptosis, migration and invasion.167,168 This is somewhat consistent with
the correlation made between FRα overexpression and a poor prognosis/aggressive phenotype and
decreased survival in ovarian cancer patients.169,170 FRα expression has been linked to many
changes seen in malignant transformation which has led some investigators to think the protein
plays a significant role in normal to malignant transition.168
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Membrane bound FRs translocate extracellular folates through receptor mediated
endocytosis. After endocytosis, the ligand bound receptor is enclosed in an endosome, which
subsequently acidifies, releasing the ligand from the receptor, after which the free ligand is
translocated to the cytosol, through some uncharacterized mechanism. There have been two
competing theories surrounding the fate of the endocytosed ligand-bound receptor: (1) clathrincoated vesicles/pits are involved in intracellular transport; and (2) a clathrin-independent
mechanism that occurs in lipids rafts which involves the development of early endosomes that
mature and acidify resulting in the release folates in the intracellular accumulation o. Many studies
support the clathrin- independent mechanism as this model appears to be congruent with observed
absorption, localization and trafficking that has been described for the receptor.110,171,172 FRs are
proposed to associate with lipid rafts which have been shown to play a role in signal
transductions;173 this offers some plausibility to the growing hypothesis that FRα is also involved
in signaling. 128,174
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Reprinted (adapted) with the permission of Chen et al.175 Copyright (2013) Nature letters.
Figure 1.9: Ribbon and charge distribution surface model of FRα complex with folic acid
substrate. (Above) The alpha and beta helices (shown in green) demonstrate how the protein
interacts with the endogenous ligand, folic acid. (Top-Right) A 90 degree rotation of the protein
offers additional information about the protein-substrate interaction and the key amino acids
involved in the folic acid recognition/binding process. (Bottom) The charge distribution surface
model illustrates folic acid contained within the binding pocket and the charge of the amino acids
surrounding the binding surface.
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1.4 Folate based targeted therapy
Shortly following the discovery and first synthetic synthesis of folic acid, folate analogs
termed antifolates were the subject of heightened attention resulting from their roles as effective
agents against hematopoietic malignancies.176,177 More specifically, the development of the first
clinically used antifolate, AMT, fundamentally changed the treatment of pediatric leukemia and
ultimately served as a platform for the development of many novel antifolates.176,178,179 The vast
and rapidly accumulating knowledge of folate metabolism also played an integral role in
understanding the pharmacology of these analogs in addition to providing direction in the
development of less toxic congeners.
Antifolates describe a class of agents that are structural analogs of folate and exert their
antiproliferative actions through inhibition of enzymes in folate metabolism, resulting in the
depletion of nucleotides required for DNA replication and DNA repair, and RNA synthesis.180
Today antifolates remain the most well-studied chemotherapy agents with well-defined and wellcharacterized mechanisms of action. The recent discovery of the molecular structure of FRα and
growing structural information about the β isoform will encourage the synthesis and development
of more sophisticated agents with the promise of achieving successful and precise tumor
targeting.175,181

The identification of malignancies that over-express ideal targetable folate

transport systems (FR’s and PCFT) are steadily growing. Recent studies that examined patient
tumor samples reveal that in vitro tumor models may inaccurately reflect the amount of folate
transporter proteins that are actually expressed in in vivo patient tumors (personal communication;
Folate Receptor Conference, Couzumel (2013)). This overexpression not only increases target
area and points of entry for FR targeted drugs, but this may also have dramatic impact on tumor
response and the concentration of drug required for efficacy.
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There has been tremendous progress in the area of antifolate development since the
introduction AMT and MTX. While these agents were the first ground breaking therapies of their
kind, there are currently a number of novel agents under investigation that target different folate
pathway enzyme and inhibit growth of neoplastic cells through the disruption of DNA synthesis.
This diverse array of compounds not only includes new and improved DHFR inhibitors that differ
from the first generation agents, AMT and MTX, such as pralatrexate, but also PMX which inhibits
TS.25,182,183 GARFTase inhibitors are under development as well.25 These novel compounds can
be grouped based on their intended enzyme target, their chemical structure and their ability to
undergo polyglutamylation.
GARFTase has become a metabolic target of increasing relevance since the inception of
lometrexol (LMTX) by the Eli Lilly Corporation in 1985.91,184 Much of the interest surrounding
LMTX and subsequent GARFTase inhibitors reflects their ability to disable the rate-limiting step
in the de novo biosynthetic pathway of purines which involves the transfer of the formyl group
from 10-formyl-THF to the primary amine of β GAR which provides the C8 carbon in the purine
skeleton.185,186 The disruption of purine production in tumor cells is believed to be a favorable
feature of a chemotherapeutic drug, as these drugs not only interfere with DNA replication but
they also disturb the cellular energy balance via ATP depletion, thereby interfering with energy
requiring processes necessary for cell viability.187 Another interesting and advantageous aspect of
many of the prototypical GARFTase inhibitors is that they were designed based on the crystal
structure of either human or E. coli GARFTase, which share homology at the folate co-factor
binding site.185 The structure-based drug design approach used for these inhibitors may account
for their characterization as “clean” drugs, in that they have a clear mechanism of action unlike
nucleoside analogs or purine based drugs that may have some influence on purine synthesis but
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also possess the capacity to be incorporated into nucleic acids, making their primary function
indeterminate.185
LMTX was the first folate-based antipurine that possessed potent inhibitory actions against
GARFTase.184 Remarkable preclinical data in xenografts of human tumors and murine models of
solid tumors aided in making LMTX the first GARFTase inhibitor that was clinically
investigated.184,188 Further development of LMTX was halted during clinical trials due to delayed
and cumulative side effects, which include severe and unpredictable myelosupression and
neuropathy that was thought to be a function of a long terminal half-life and liver
accumulation.91,184,189 RFC-directed transport of LMTX may have been an additional contributing
factor to toxicity seen in patients.189 Folic acid supplementation was shown to curtail these
adverse side effects and allowed patients to tolerate higher concentrations of drug. 184 In light of
this, new dosing schedules with co-administration of folic acid were implemented in additional
studies using this drug.190,191 However, further clinical development of LMTX was brought to a
standstill, reportedly for economic reasons.192
The LMTX studies validated GARFTase as an important target in de novo purine
biosynthesis. In efforts to create novel GARFTase inhibitors that maintained the potent biological
activity of LMTX, but with reduced untoward toxicities, computer assisted drug design was used
to create AG2034 and AG2037.

The GRID program, a computer generated method for

systematically investigating an array of chemical groups and how they interact with suggested
protein binding sites, revealed two hotspots at the GARFTase binding site that possessed an
affinity for a thioester probe.185 The structure of human GARFTase was the model for drug
design.193 The sulfur containing AG2034 was designed to complement the two identified hotspots
at the GARFTase active site identified by the GRID program.185 AG2034 possessed promising
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characteristics of an ideal GARFTase inhibitor, with a Ki of 28 nM against the human enzyme,185
and the ability to undergo polyglutamylation.185,193 Together, these attributes are thought to be
responsible for the potent antiproliferative activity seen in L1210 cells (IC50:4 nM) and CCRFCEM cells (IC50:2.9 nM).193 Cells with a mutant p53 and/or those lacking a functional G1
checkpoint were particularly sensitive to purine deprivation elicited by this drug (A549 and MCF7).194 After being selected for preclinical trials and tested against a range of murine tumors and
human xenograft models, AG2034 was taken to clinical trials. These initial trials were suspended
to investigate the newer analog AG2037. AG2037, like AG2034, is a sulfur containing GARFTase
inhibitor. However unlike, AG2034 and LMTX, which can achieve cellular entry through both
RFC and FR, AG2037 is transported by RFC exclusively.185 The selective transport by RFC was
thought to be ideal at the time. This was supported by a belief that efficacy of drugs that undergo
FR-mediated transport would be modified based on the nutritional status (folate intake) of the
patients.185 A clinical trial with AG2037 in colorectal cancer patients that failed treatment was
completed in 2004, however this study has no posted or published results to date.
Attempts to develop improved GARFTase inhibitors continued with the creation of Eli
Lilly’s GARFT II, also referred to as LY309887. When compared to LMTX, LY309887 had a 9fold greater potency but produced metabolites with reduced polyglutamylation.188 To address the
issue of polyglutamylation, two monoglutamate GARFTase inhibitors were introduced,
LY254155 and LY222306. LY254155 and LY222306 are 2’, 5 thiophene and 2’, 5 furan
derivatives of LMTX, respectively.

These compounds exhibited greater inhibition against

GARFTase when compared to the parental compound LMTX and both possessed reduced affinity
towards FRα (LY254155: 6 fold, LY222306: 350 fold).195 These agents would presumably be
valuable in the treatment of tumors with inherently low FPGS activity or tumors that have acquired
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resistance to antifolates through reduced expression and or function of FPGS or increased gamma
glutamyl hydrolase activity.195 The search for an efficacious but well tolerated GARFTase
inhibitor is ongoing and recent developments in folate transport proteins may produce a generation
of equally as effective but targeted agents.
Currently, there is no antifolate that uses AICARFTase as its primary target. While the
multi-targeted antifolate, PMX, inhibits AICARFTase as a secondary target, the extent of enzyme
inhibition by this drug has not been directly quantified.196,197 The rising and alarming acquired
resistance to current antifolate therapies through multiple mechanisms, including overexpression
of enzyme targets and decreased expression of essential transport proteins. The need to circumvent
antifolate resistance encouraged the design of novel AICARFTase and GARFTase inhibitors
(among the most infrequently targeted enzymes in folate metabolism) that use an alternative
mechanism of cellular entry.158
FR targeted drugs
Experimental evidence from the Matherly lab and a host of others have shown that classical
antifolates like MTX, LMTX and PMX bind, at varying degrees, to FRα and elicit a cytotoxic
effect in FRα-expressing cells, albeit at different concentrations.136,198 Increasing concentrations
of these agents may introduce off target effects, making it difficult to ascertain if the toxic effects
were FRα-mediated or otherwise.

Most of the drugs in this class are transported by the

ubiquitously-expressed RFC, which is thought to lead to intestinal and bone marrow toxicities as
these are highly proliferative tissues with an increased dependence on the very enzymes these
drugs inhibit.136
The adverse effects of these drugs were thought to arise, at least in part, from their RFC
transport. This created demand for agents that would reduce undesirable toxicities in normal cells.
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Ovarian and endometrial cancers were recognized for their expression of FRα and were considered
difficult to treat with available therapies. These factors may have led to the quest for FRα-targeted
therapies. In the 1980s, efforts to design a FR-based antifolate culminated in the development of
the TS inhibitor CB3717.199 This agent showed preferential transport by FRα over RFC and could
be metabolized to polyglutamates, but further development of this compound was halted due to
nephrotoxicity (thought to be a product of insolubility associated with high dose administration
rather than FRα transport) and myelosupression.200
The cyclopenta(g)quinazoline based drug, CB300638, became the first validated FRα
targeted TS inhibitor.136 This agent showed high selectivity for FRα when compared to related
analogs, and showed efficacy in a physiological folate concentration (20 nM) and inhibited TS in
KB cells but did not compromise normal tissue.201

BCG 945, like CB300638, also a

cycoplenta(g)quinazoline based compound, showed inhibitory effects against TS in FRαexpressing cells.202 Due to its in vitro and in vivo efficacy and FRα selectivity, BCG 945 was
selected as a candidate for phase I clinical trials that are currently on going.202
De novo purine synthesis has become a rather attractive target in non-RFC based therapies
with the development of novel GARFTase inhibitors that possess selective membrane transport
for FRs and PCFT over RFC. The circumvention of RFC membrane transport by a collection of
agents within this category can be seen as an improvement upon earlier agents such as LMT which
was reported to induce severe myelosuppression in clinical trials, likely due to RFC transport.
Both FR- and PCFT- targeting have distinct advantages that include narrow tissue expression
(PCFT and FR), optimal performance in tumor acidic microenvironment (PCFT) and basolateral
expression (circulation accessible) expression only seen in tumor cells (FRα). These pyrrolo[2,3d]pyrimidine compounds are currently undergoing development, but show extraordinary potency
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toward PCFT- and FRα- positive engineered cell lines, as well as towards PCFT- and FRαexpressing tumors in both in vivo and in vitro models.198,203-207
Monoclonal antibodies
FRα-specific monoclonal antibodies have been developed for both therapeutic and
diagnostic applications.208 One of the first antibodies directed to FRα was the murine LK26 whose
further development was impeded by the inability to create a humanized version that maintained
a suitable affinity towards FRα.208 Farletuzumab (MORab -003), the improved humanized
“offspring” of LK26, is a composite of murine complementary determining regions into the human
IG-1 Kappa backbone.125,208,209 This improved congener retained its high affinity to FRα with
limited reactivity to normal tissue. Farletuzumab’s proposed mechanism of action is through
complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity
(ADCC).125

The antibody is also thought to inhibit cell proliferation through suggested

interactions with Lyn kinase and membrane signaling complexes that act to inhibit growth.208,209
The binding of farletuzumab does not interfere with FRα binding to its ligands and was reported
to marginally reduce the rate of folate delivery, which may offer opportunities for use in
combination treatment with other FR directed therapies.
Farletuzumab is reported to be a well-tolerated drug with adverse effects that are well
managed with antihistamine treatment.208 When used in combination with carboplatin/taxane
treatment, there was reported clinical activity and improved duration of response when treatment
was followed with the single agent maintenance with farletuzumab.125 No safety concerns or doselimiting toxicities have been reported for farletuzumab and a maximum tolerated dose has not yet
been identified.208
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Folic acid-conjugated therapies
Folic acid conjugated therapies present a platform to repurpose potent but non- specific
cytotoxins for delivery in a context that allows for target specificity. The γ-carboxylic group on
the folic acid permits linkage of a “warhead” (potent cytotoxin) without disturbing the affinity of
the ligand to the target.208 Like monocolonal antibodies, folic acid conjugates can be used for
imaging/diagnostic purposes or therapy, all which is dictated by the conjugate compound. An
excellent example of this is seen in vintafolide (EC145) and etarfolatide (EC20) developed by
Endoycote.

Vintafolide is a folic acid conjugate comprised of a potent vinca alkaloid,

desaceytlvinblastine hydrazine “warhead” and etarfolatide is a folic acid conjugate containing the
medical radioisotope technetinum 99m.210-212 Vintafolide was shown to be most effective (~80%
overall response rate) in ovarian cancer patients who showed high detection of FRα positive tumors
by etarfolatide.213 While 90% of ovarian cancers overexpress FRα, there is much variation in the
level of expression among individuals and subtypes of the disease. Imaging with etarfolatide will
aid in the identification of patients who would most benefit from this form of FR-targeted
treatment. While these agents performed well in phase I and phase II clinical trials, a phase III
clinical trial in platinum resistant ovarian cancer was halted due to the failure to produce proper
efficacy (an improvement in progression free survival).
Cytotoxic warheads are not limited to the vinca alkaloids. Promising pre-clinical data were
obtained from EC0746, a modified folic acid ligand linked to a γ hydrazide analog of AMT. The
compound was directed towards FRβ expressing activated macrophages in murine models of
autoimmune uveitis and encephalomyelitis and showed significant activity through macrophage
modulation.214 The concept of re-directing RFC-transported cytotoxic antifolates to alternative
routes for uptake, like FRα, is a very attractive idea. FRα-mediated uptake by a multi-targeted
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antifolate, like PMX, may allow ovarian cancer patients to benefit from the activity of this drug
without the consequence of its debilitating side effects.
Novel pyrrolo[2,3-d]pyrimidine antifolates
Pyrrolo[2,3-d]pyrimidines define a collection of heterocyclic compounds that share a
common heterocyclic fused-ring structure.

These compounds may vary in respect to their

physiochemical properties as many of them participate in a wide range of biological activities, that
include functioning as kinase inhibitors215-217, metabolic inhibitors204,205,207,218 and modulators of
efflux pumps that are often referred to as multi-drug resistance proteins, MRP1s.219 The diverse
actions of pyrrolo[2,3-d]pyrimidine compounds are thought to be dictated by the addition of
functional groups (R-group or substituents) at the C4-C7 positions on the molecule218 (Figure
1.10a). Studies performed in this body of work as well as earlier studies published by Matherly
and colleagues203-205,207,220,221 suggest that the chemical and structural properties of the R-groups
have a tremendous impact on pharmacology of these molecules.
Pyrrolo[2,3-d]pyrimidines are naturally occurring compounds that can be synthesized by
variety of organisms including marine and terrestrial bacteria222. The pyrrolo[2,3-d]pyrimidine
compounds synthesized by these organisms (also referred to 7-deazapurines) are described as
secondary metabolites because of their non-essential role in primary metabolism; however these
compounds are thought to provide an advantage to the organism when present in a host.222 7deazapurines are found to be involved in the disruption of cellular process that involve adenine
nucleosides and nucleotides and were also discovered to perturb cellular metabolism. These
compounds are suitable substrates for phosphorylation and can be converted into di-, triphosphorylated forms which can then be incorporated into DNA and or RNA as modified bases.222
Together, these features have made these compounds useful tools against bacterial223, fungal and
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viral infections as well as neoplasms.224,225 Toyocamycin, tubercidine and sangivamycin are all
soil derived 7-deazapurines which contain the pyrrolopyrimidine scaffold with different
substituents making the action of each compound distinct from the other (Figure 1.10b).
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Adpated with permission of McCarty et al. Copyright (2012) Bioorganic Chemistry
Figure 1.10: Pyrrolo[2,3-d]pyrimidine scaffold molecule. (A) The pyrrolo[2,3-d]pyrimidine
scaffold can be substituted at multiple carbons sites (C4-C7). The addition of these R-groups have
been reported to confer selective physiological properties157. Highly saturated scaffolds
demonstrate greater biological activity.218 The diversity in function derived from the addition of
functional groups is beautifully illustrated by toyocamycin, tubercin and sangivamycin (B), a few
of many naturally occurring 7-deazapurines, which have unique cytotoxic, antibacterial and
antifungal properties while possessing one distinctive R-group.
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Pyrrolo[2,3-d]pyrimidine antifolate compounds, like the naturally occurring soil
metabolites, can be functionally malleable based on the functional group added and the position at
which the functional group is added. The lack of crystallographic information for all three forms
of folate transport proteins necessitated high throughput screening of pyrrolo[2,3-d]pyrimidine
compounds that showed activity against cell lines engineered to express one of the three transport
mechanisms. From such studies, rational drug designs, based on both the biological activity of the
compounds studied and the known structure of folate metabolism proteins GARFTase and TS,
created a number of pharmacologically interesting compounds. The recent determination of the
FRα crystal structure offers promise to structure-based drug design which will prove invaluable to
FR-directed therapies and imaging modalities (Figure 1.9).
Studies performed by the Matherly lab using novel pyrrolo[2,3-d]pyrimidines synthesized
by Dr. Aleem Gangjee and colleagues at Duquesne University (Pittsburgh PA), demonstrated
qualities consistent with that of a classical antifolate, in that membrane transport by RFC, PCFT
or FR could be identified and their antiproliferative capacities could be linked to the inhibition of
enzymes involved in folate metabolism. The position of the substitution on the fused heterocyclic
ring appears to play an important role in determining the substrate specificity of enzymes in folate
metabolism, as well as the route of intracellular transport.198,203-207,220,226 Earlier studies performed
by Gangjee and colleagues suggested that a novel 2-amino-4 oxo-5-substituted pyrrolopyrimidine
compound possessed antitumor activity against human head and neck squamous carcinomas and
CCRF-CEM human leukemic cell lines.227 The antitumor effect was thought to be a function of
TS suppression, indicated by purified enzyme assays and metabolite protection assays.227
Alternatively, collaborative studies with the Matherly lab using 6-substituted pyrrolo[2,3d]pyrimidines antifolates active against both engineered CHO cell lines and human tumor cell
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lines expressing folate transporters, demonstrated inhibition towards GARFTase. GARFTase
suppression was demonstrated via metabolic nucleoside protection assays as well as radioactive
metabolic incorporation assays and isolated enzyme assays.198,205,220 Further, these studies also
revealed that drug activity can be dictated by the length of the carbon bridge region which connects
to either a thienoyl or benzoyl ring system. These studies provided greater insight into the
structural components required for folate-based targeted drug activity.
The most potent, tumor-targeted analogs from these studies were lead compounds AG23,
AG71, and AG94. These three compounds represent three distinct series of novel pyrrolo[2,3d]pyrimidine antifolates. While structurally unique, each of the lead compounds was found to
have

profound

antitumor

activity

against

FRα

and

PCFT

expressing

cell

lines

(nanomaolar/subnanomolar range) with minimal or greatly reduced activity towards RFC
expressing cell lines.198,203-206

These antipurines are effective inhibitors of de novo purine

synthesis as the studies cited above demonstrated remarkable dose-dependent inhibition of
GARFTase. Mindful of the impressive targeted antitumor activity of these leads, congeners of
these compounds are thoroughly investigated in this body of work to determine how structural
modifications impact membrane transport, inhibition of targeted enzymes and ultimately cell
death.
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Reprinted with the permission of Mitchell-Ryan et al. (2013). Copyright. J Med Chem.
Figure 1.11: Structure of lead compounds from three distinct series of novel antifolates. Each
compound depicted in this figure contains the 2-amino-4-oxo fused hetercyclic ring structure
(pyrrolo [2,3-d]pyrimidine). Both AG71 and AG94 conclude their carbon bridge with thienoyl
ring system unlike AG23 that contains a benzoyl ring in its second ring system. Each compound
is substituted at the 6 position. All novel pyrrolo[2,3-d]pyrimidine compounds presented in this
work were synthesized by the lab of collaborating medicinal chemist Dr. Aleem Gangjee.
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1.5 Ovarian cancer
Gonadal tissues in the female reproductive tract originate from mesoderm layer of
embryonic tissue. A vast majority of the female reproductive tracts is developed from the
paramesonephric duct, also known as Mullierian ducts, which is responsible for the formation for
approximately two thirds of the female reproductive tract.228

The ovaries, however, are

descendants from the genital ridge and are involved in the production of eggs and the hormones
that help to nurture and prepare eggs for ovulation.229 During ovulation, the eggs travel through
the Fallopian tube to the uterus where they await fertilization. There are a host of hormones,
cytokines and cells that are involved in the cyclical transition of ovulation and menstruation, some
of which are thought to be influential in ovarian pathogenesis.230-232
Ovarian cancer is a rare but very lethal gynecological pathology in the United States. While
the lifetime risk of developing ovarian cancer is 1.6%, the majority of the women diagnosed will
ultimately die from the disease, as it is the fifth leading cause of cancer death in American
women.232,233 The American Cancer Society 2014 statistics estimates that there will 21,980 new
cases of ovarian which is a negligible decrease from the 2013 estimate of 22,240 cases.233,234 While
there has been a slight decline in the estimated rate of incidence, the mortality rates remain
staggering with the 2014 estimate of 14,270, which is a slight increase from the 2013 estimate of
14,030 deaths.233,234 A vast majority of women diagnosed present at late stage with aggressive
disease that is often inclined to recur as a fatal treatment resistant disease. There are a number of
factors that contribute to late stage (stage III/IV) diagnosis including the lack of appropriate and
reliable screening modalities and the mismanagement of primary disease. The mismanagement of
ovarian cancer, which generally entails the failure to direct patients to experienced gynecological
oncologists for optimal cytoreduction strategies, has a direct impact on the mortality disparities
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that exist between populations within this disease.235,236 The molecular profiles of ovarian cancer
are identical among African-American and Caucasian women, suggesting that there are no genetic
factors leading to a more aggressive phenotype for African-American women.236,237 However, the
mortality rates are higher among African-American women, which some believe is a function of
mismanagement of disease, unequal application of existing treatments and the perceived socioeconomic status of the patient.235,236,238
Late stage ovarian cancer presents a host of treatment challenges. An overwhelming
majority of patients are diagnosed with late-stage ovarian cancer which is no longer confined to
the ovary. At this time, treatment options are limited and are generally ineffective with gross
toxicities to the patients. Depending on the extent of tumor burden, surgical reduction no longer
exists as an option.236 An additional determinant in choosing a candidate for debulking surgery is
the presence of comorbidities that are contraindications for the procedure.239,240 Independent of
these conundrums, approximately 90% of patients that show initial response to first-line
platinum/taxane therapy will experience a recurrence of treatment resistant disease.240
The term ovarian cancer serves an umbrella to describe a collection of malignant tissues
that are distinguishable by cell type and more recently, by specific molecular events. These
subtypes correspond to different types of epithelia and organs within the female reproductive
system. Traditionally, ovarian cancers were separated in to three major subtypes based on their
histology, including: (1) surface epithelium which includes serous, mucinous, endometroid, clear
cell and Brenner tumors; (2) sex cord-stroma which includes granulosa cell, sertoli cell , sertoli
leydig , thecoma, fibroma and steroid tumors; and (3) germ cell tumors that include dysgerminoma,
yolk sac, embryonal carcinoma, choriocarcinoma and teratomas.241 In line with the initial system
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of categorizing these tumors, they were further characterized based on clinical behavior as benign,
malignant and intermediate.242
Congruent with the general principles of carcinogenesis, ovarian cancer is typically a
disease of aging with the median age of diagnosis at 63 years.243 Epithelial ovarian cancer (EOC)
is the most common form of this disease that accounts for 90% of ovarian cancers.213 Historically
this subtype of ovarian cancer was thought to arise from ovarian surface epithelium (OSE).244-247
This early perspective on ovarian cancer suggests that OSE is capable of phenotypic plasticity
which is derived from the numerous histological transitions that begin with a stromal ovarian
epithelial inclusion cyst (OEI).247 Through metaplasia, this cyst acquires a Mullerian phenotype
which eventually evolves into a malignant transformation resulting in the multiple subtypes of
EOC.247 Critics of this theory express skepticism due to (1) the failure to identify an ovarian
precursor lesion and (2) there are no reported observations of the transition of an OEI to multiple
EOC subtypes.247 Further, OSE shows no resemblance to EOC and is distinct from Mullerian
epithelia.247 However proponents of this theory offer a theory based on experimental models and
histopathology that suggests that tumor promoting agents have the ability to transform OSE to
malignant tumors.246
A growing number of reports suggest that the ovaries serve only as a secondary site and
that the premalignant lesion is formed at a primary site adjacent to the ovaries.232,247-256 The
“Secondary Mullerian System Theory” was the first suggestion that ovarian cancer originates from
an alternate tissue of origin.257 This theory suggest that pelvic tumors with a mullerian phenotype
(like many ovarian cancers) originate or are derived from mullerian type epithelium (uterus, cervix,
Fallopian tubes) directly by a metaplastic process.247 This theory fostered the hypothesis that most
EOC begin as precursor lesion in the distal Fallopian tube.
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High grade serous carcinoma (HGSC) is the most common and lethal subtype of EOC,
accounting for 70-80% of the cancers within this category (clear cell carcinoma and endometroid
carcinoma accounts for 10 %).213,232,247 HGSC frequently displays p53 mutations and genomic
instability.213,247 This is in stark contrast to type I low grade carcinomas, which include low grade
serous carcinoma, low grade endometroid carcinoma, clear cell carcinoma, mucinous carcinoma
and Brenner tumors. 211 Type I tumors are described as a clinically non-aggressive disease that
generally present at early stage. 209,243 Type I tumors rarely contain p53 mutations and are typified
by mutations involving KRAS, BRAF, ERBB2, PTEN, CTNNB1, PIK3CA, ARID1A and
PPP2R1A.213,247 Type I and Type II tumors are distinguishable not only by molecular markers,
but they differ in presentation, metastatic potential, response to therapy and prognosis.232
There have been a number of observations that support Fallopian tube involvement in
ovarian cancer, many of which include the identification of putative precursor lesions. BRCA1/2
mutant carriers have a 30-60% increased risk of EOC.232 In one study that examined the Fallopian
tubes of asymptomatic BRCA1/2 mutation carriers along with women from the general population
diagnosed with pelvic serous carcinoma, identified at least one of three putative precancerous
lesions; they include: (1) serous tubal intraepithelial carcinoma (STIC) in the Fallopian tubal
frimbria; (2) p53 signatures; or (3) frimbrial secretory outgrowth.247 STIC are generally located
at the distal end of the Fallopian tube and are characterized by frequent p53 mutations, increased
cell proliferation, DNA damage and a secretory phenotype.252,253,258,259 The multiple shared
characteristics of STIC to HGSC are believed to be suggestive of a histological relation between
the two. Similarities in copy number changes, tubal involvement in HGSC cases, a shared
secretory phenotype of STIC and HGSC all serve to support the hypothesis that HGSC is the clonal
outgrowth of STIC lesions.247,260,261 Further, there is a dramatic 98% reduction of ovarian,
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Fallopian tube and primary peritoneal cancer risk in BRCA1/2 carriers that underwent prophylactic
bilateral salphingo-oophorectomy which involves the removal of both the ovaries and the
Fallopian tubes.232 The Sectioning and Extensively Examining the FIMbria protocol (SEE-FIM)
which was put in place to maximize the detection of precursor lesions in early Fallopian and
ovarian cancer, demonstrated that women diagnosed with ovarian or primary peritoneal HGSC
present with STIC (40-60%) that have identical mutational status observed in tumors and also
show evidence of tubal involvement (70%).232 Altogether, these studies provide a convincing link
to HGSC and the Fallopian tubes, and point to STIC as the initiating lesion that leads to this
aggressive cancer.
The ovaries are believed to be the secondary tumor site for disease that originates in the
Fallopian tubes. The proposed mechanism by which this occurs is thought to involve the shedding
of STIC cells from the distal Fallopian tubes onto the nearby ovaries during ovulation.247 While
trapped in the ovary, these pre-malignant Fallopian tube-derived cells thrive in the ovulatory
environment where they are exposed to hormones, pro-inflammatory cytokines and reactive
oxygen species (ROS) which all may aid in the clonal expansion or re-initiation of cell proliferation
in the ovary.230,247 This proposed mechanism has helped to construct a new model for the
development of HGSC which differs from the step-wise development observed in type I low grade
carcinomas.247
An additional feature of EOC (including 90% of HGSC) is the overexpression of FRα. In
1991, amino acid sequencing analysis determined that the protein enriched on the surface of nonmucinous ovarian cancer was FRα.213 This identification led to the emergence of the FR protein
as a tumor marker for this cancer.213 The surface expression of the FRα protein corresponded with
grade and stage of the tumor.170,262,263 Interestingly, tumors (with some degree of FRα expression)
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treated with chemotherapy (i.e., MTX, tamoxifen and cisplatin/carboplatin) experienced increased
(MTX, Tamoxfien) or stable (cisplatin/carboplatin) expression of FRα.264 Knowing this, drugs
that selectively target FRα can be used as adjuvant therapy in situations where first-line therapies
have failed.
Currently, there is no widely accepted comprehensive tumor progression model for ovarian
cancer, which presents a myriad of challenges in studying this cancer.265 Cell line models (Table
1.1) and mouse models of ovarian cancer, which are the existing experimental tools, have their
limitations and in some cases fail to accurately represent the in vivo (patient) tumor. Molecular
profiling of ovarian cancers has allowed research to distinguish between high grade (type II) and
low grade (type I) tumors.266,267 This categorization of tumors based on molecular markers has
called into question the true histopathology of many of the human ovarian cancer cell lines
currently used in research.268 Cell line contamination may also be a factor contributing to the
conflicting reports and misidentification concerning the histopathology of these experimental cell
lines.269,270 Mouse models of human ovarian cancer make the assumption that the ovary is the
primary site of disease. The current models attempt to create tumors in the ovary through the use
of promoters, many of which are described as leaky.271 Ex vivo implants and use of transgenes
arguably do not mimic the natural evolution of human EOC and are not representative disease
models.271 The limitations inherent in both in vivo and in vitro models present an opportunity for
the development or the investigation of a new model that incorporates an identified and validated
precursor lesion.
While there may be continued debate over the etiology of ovarian cancer and the utility of
the models currently used to study the disease, reproductive, genetic and environmental factors
continue to be implicated as risk factors in this multifactorial malignancy. Like most other cancers,

63

increasing age, inherited genetic cancer syndromes and family history remain important
determinants of ovarian cancer risk.272
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Cell line
KB
IGROV-1

SKOV-3

Clinical pathology
Clinical relevance
Nasopharyngeal
carcinoma

References
Round et al. 1970,273
Kou et al. 2003,274
Jhaveri et al. 2004
HGSC (Kulbe, Domcke)
Kulbe et al 2012,275
Serous (Gloss, Dejardins)
Dejarins et al 2014,276
Gloss et al 2014,277
Polymorphous
adenocarcinoma:
Benard et 1985278
endometroid,clear
cell, Domcke et al. 2013268
serous and undifferentiated
foci (Benard)
Ueda et al 2010,279
HGSC
Anglesio et al. 2013,280
Tsofade et al. 2013,281
Jiao et al 2011282
Domcke et al. 2013268
Ueda et al 2010,279

OVCAR-3

HGSC

CAOV-3

Tsofade et al. 2013,281
Berger et al. 2001,283
Domcke et al. 2013268
Gloss et al 2014277
Berger et al. 2001,283
Serous carcinoma
HGSC (Berger, Domcke)
Gloss et al. 2014,
Domcke et al. 2013268
Aggressive
stage
III Gagne et al 2007,284
endometroid tumor

TOV-112D

Table 1.1: A Commonly used FRα positive cell line model with commonly used
ovarian cell line models. The table above contains human ovarian cancer cells lines (and one FR
model, KB) commonly referenced in research literature.
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Reproductive risk factors
Ovulation has been thought to contribute to malignant transformation of the epithelium due
to proliferation that occurs during this process.

This proliferation is believed to promote

carcinogenesis via the accumulation of genetic mutations in a repetitive “trauma-and-repair”
cycle.265,272 Therefore, agents that reduce ovulation should have a protective effect against the
development of disease.285-287 Indeed, oral contraceptive use has been shown to have an inverse
relationship with ovarian cancer risk in a number of epidemiological studies.285-287 Gestation also
temporarily suppresses ovulation; therefore parity, number of pregnancies and long term breast
feeding have all been reported to have protective effects against the development of ovarian
cancer.265,272,288
Genetic risk factors
Women with a family history of ovarian cancer have an increased risk of cancer
development. Women with one or more first-degree relatives with ovarian cancer have an
increased life-time risk of ovarian cancer development of 5-9%.272 Hereditary cancer syndromes,
like BRCA1/2 mutations, also dramatically increases the risk of developing ovarian cancer;
however, this only accounts for approximately 5-12% of cases.289 Most ovarian cancer cases arise
from sporadic mutations that may not be associated with genes found in hereditary breast and
ovarian cancer (HBOC) and hereditary nonpolyposis colorectal cancer (HNPCC) syndromes.265,272
Aberrations in TP53, HER2, EGFR, DAB2, AKT, RAS, MYC, PI3K and AR have been suggested
to play some role in sporadic cases129,130 , yet mechanistic details of their involvement in
carcinogenesis have not been thoroughly investigated.
Environmental risk factors
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Obesity is a common modifier of cancer risk in nearly all types of cancer. Obesity has
been linked to inflammation and there is mounting evidence that links both obesity and
inflammation to cancer risk. 129,130 Pelvic inflammatory disease and endometriosis exposes the
ovaries and other reproductive organs to prolonged inflammation that may increase ovarian cancer
risk.290-294
There have been conflicting reports on the role that genital talcum powder exposure plays
in the development of ovarian cancer.295 The source surrounding much of this controversy lies in
the fact that prior to 1976 talc was contaminated with asbestos and much of the data was thought
to be confounded due to the presence of cancer causing substance.295 However, it has been
postulated that ovarian cancers can arise from exposure to hydrous magnesium silicates (e.g.,
talcum powder) and recent findings are not tainted by the asbestos association.295,296 Cancerous
ovaries removed from patients have been shown to contain traces of talc.272
Early detection and prevention
To date, there is no reliable screening method to detect early stage ovarian cancers.
Transvaginal ultrasounds, CA (Cancer Antigen)-125 serum levels and pelvic exams are the
primary detection/screening tools.129,130,297 Together, these methods are deemed inefficient or
inadequate due to their inability to capture subtle changes that may occur during tumor initiation
and early cancer progression in ovarian cancer.297 These modalities also fail to possess the
specificity and sensitivity required for practical positive predictive values.297 The absence of a
defined and validated precursor lesion only adds to the challenge in developing a proper screening
modality.129,130 There are currently efforts to identify new biomarkers to replace or to use in
conjunction with tools that are currently available.298
Current treatments for ovarian cancer
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Ideally, patients who are declared good surgical candidates are recommended for
cytoreductive surgery followed by adjuvant chemotherapy.129,138,139 Unfortunately, at stages I-II
of disease, patients with EOC are asymptomatic or symptoms are easily mistaken for innocuous
conditions.299 This, in conjunction with the lack of adequate early detection screening, results in
infrequent early stage-diagnosis.129,

297,139

Vaginal bleeding/discharge, frequent urination and

constipation are typical symptoms of early stage ovarian cancer but are often ignored because they
are common symptoms of less severe minor gynecological abnormalities.129 Approximately 1.5%
of patients present with early stage disease for whom complete surgical removal of the tumor can
be successful and survival is greater than 90% (when cancer is confined to the ovaries); therefore,
chemotherapy is the primary treatment option for a vast majority of cases.129, 130, 297,300 Over the
past 40 years, standard therapies used to treat EOC have not significantly extended the median
overall survival beyond 25-30% in women diagnosed with advanced disease.130,137 Approximately
75-80% of ovarian cancers exhibit initial chemotherapy sensitivity to first line taxane- and
platinum-based agents (paclitaxel/docetaxel and cisplatin/carboplatin). However, most of these
patients will experience relapse within a year.258,301 Due to the chronic recurring nature of EOC,
treatment strategies should allow for prolonged treatment by using agents with low toxicity
profiles, to ensure reasonable patient comfort and minimal disruption to the quality of life for the
patient.
There are well recognized cumulative and sometimes irreversible toxicities associated with
these standard agents (regardless of method of delivery) which makes additional treatment with
these classes of agents intolerable for patients, thereby reducing the available options in treatment
and creating a precipitous decline in patients’ quality of life.300-302 Hematological and neurological
toxicities are of greatest concern as they may impede the patient’s ability to carry out everyday
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activities. With this in mind, there is growing support to include “improved quality of life” along
with “duration of survival” as major considerations in the therapy of advanced cancers.300
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CHAPTER 2: DISCOVERY OF 5-SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINE
ANTIFOLATES AS DUAL ACTING INHIBITORS OF GARFTASE AND AICARFTASE
IN DE NOVO PURINE NUCLEOTIDE BIOSYNTHESIS:
IMPLICATIONS OF
INHIBITING AICARFTASE TO AMPK ACTIVATION AND ANTI-TUMOR ACTIVITY
2.1 Introduction
The antifolates are widely recognized for their inhibition of folate metabolism that leads to
growth suppression, tumor reduction and remission in a number of malignancies and the reduction
of inflammation in pro-inflammatory conditions.38,303,304 Major enzyme targets of this particular
class of agents include TS and DHFR. Inhibition of these enzymes suppress de novo nucleotide
biosynthesis, resulting in an imbalance of purine and pyrimidine precursors, rendering cells
incapable of undergoing accurate DNA replication, ultimately resulting in cell death. Clinically
relevant TS and DHFR inhibitors, typified by PMX, and MTX (Figure 2.1) and pralatrexate,
respectively, continue to play important roles in treating hematologic malignancies and solid
tumors.25,303
Antifolates targeting de novo purine nucleotide biosynthesis were also described and
include LMTX [(6R)5,10-dideazatetrahydrofolate] (Figure 2.1), (2S)-2-[[5-[2-[(6R)-2-amino-4oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]thiophene-2carbonyl]amino]pentanedioic acid (LY309887)188,305 and (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo1,6,7,8-tetrahydropyrimido[5,4-bate][1,4]thiazin-6-yl]ethyl]thiophene-2carbonyl]amino]pentanedioic acid (AG2034).183 These drugs inhibit the first folate-dependent
step in purine biosynthesis, catalyzed by GARFTase, and have progressed to clinical trials.69,306,307
However, their toxicities were dose-limiting, most likely a consequence of their cellular uptake
and metabolism to polyglutamates in normal tissues.
The RFC is one of three principal mechanisms of (anti)folate uptake into mammalian
cells.308 Cellular requirements for folate cofactors for DNA replication provide a plausible
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explanation for the high levels of RFC in most tumors. However, demands for folates, and
consequently RFC, are also shared by normal tissues, such that RFC may not be the optimal
mechanism for tumor-selective uptake of cytotoxic folate analogs.

Other cellular uptake

mechanisms, notably the PCFT and FRs α and β, are also expressed in tumors, while showing
more restricted expression in normal tissues.92 Furthermore, PCFT is a proton symporter such that
in the acidic microenvironment generated by glycolytic tumors, membrane transport and selective
tumor targeting by this mechanism is enhanced.75,88 For FRα, the apical spatial orientation in
normal epithelial tissues is often disrupted in tumors such that its basolateral membrane expression
in tumors results in exposure to the circulation.88,92 These features provide compelling rationale
for developing folate-based therapeutics which target PCFT and FRα for cancer therapy.
Examples of FRα-targeted therapies include a monoclonal antibody [Farletuzumab
(Morphotech)]138,

a

cytotoxic

folate

conjugate,

N-[4-[[(2-amino-1,

4-dihydro-4-oxo-

6pteridinyl)methyl]amino]benzoyl]-L-(-glutamyl-L-α-aspartyl-L-α-aspartyl-L-cysteine

[e.g.,

Vintafolide (EC145; Endocyte)],211 and a classical antifolate which is selectively transported into
cells by FRs over RFC and inhibits de novo thymidylate biosynthesis, [(2R)-2-((4R)-4-carboxy-5(4-((2-(hydroxymethyl)-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)(prop-2-yn1-yl)amino)phenyl)-5-oxopentanamido)pentanedioic acid] (ONX0801).202
PMX is a 5-substituted pyrrolo[2,3-d]pyrimidine antifolate with a 2 carbon bridge linked
to a p-aminobenzoyl glutamate. PMX is a good transport substrate for RFC and among the best
PCFT substrates,69,75,92 yet it is a modest substrate for FRs.198,205-207,220 We previously described
6-substituted pyrrolo[2,3-d]pyrimidine benzoyl antifolates related to PMX (compounds AG17,
AG23, AG71 and AG94 (Figure 2.2).198,204

Whereas the 6-regioisomer of PMX was

pharmacologically inert, the 3- and 4-bridge carbon analogs of this series (compounds AG17 and

71

AG23, respectively) were selectively transported by FRα- and PCFT over RFC and were potently
inhibitory toward FRα- and PCFT-expressing tumor cells.113,117

Subsequent generation 6-

substituted pyrrolo[2,3-d]pyrimidine thienonyl antifolates (compounds AG71 and AG94) with 3and 4- carbon bridge lengths, respectively, were even more potent as inhibitors of cell proliferation
then that of the corresponding benzoyl analogs203,207,226. Compounds AG17, AG23, AG71 and
AG94 all showed substantial PCFT membrane transport activity but not for RFC.
PMX was originally described as a “multi-targeted” antifolate with a primary inhibition at
TS and secondarily at GARFTase and DHFR.309 However, recent studies suggested that although
TS was the primary cellular target of PMX, AICARFTase could be a pharmacologically important
target in the presence of excess thymidine (circumvents TS) at sufficiently high PMX
concentrations.196,197 Hence, in the presence of thymidine, inhibition of proliferation of CCRFCEM leukemia cells and solid tumor cell lines was circumvented by hypoxanthine but only
partially by AICA which is metabolized to ZMP, the AICARFTase substrate.170,171 Further, PMX
resulted in marked accumulations of ZMP. By contrast, the 6-substituted pyrrolo[2,3-d]pyrimidine
analogs AG17, AG23 AG71 and AG94 are inhibitors of GARFTase whose inhibitory effects are
completely circumvented by AICA.113,117,207,226
The accumulation of ZMP in PMX-treated cells is intriguing as ZMP is an AMP mimetic
that activates AMP-activated protein kinase (AMPK).310 AMPK negatively regulates mTOR, a
critical pro-survival pathway that is activated in many tumor cells along with PI3K/AKT,
secondary to loss or mutation of PTEN.310-312 This may provide a possible explanation for the
inhibitory effects of PMX in the presence of thymidine, as purine nucleotides are not
depleted.170,171 However, this has not been directly tested, as no AICARFTase-targeted drugs
without TS inhibition have been described.
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Reprinted with the permission of Mitchell-Ryan et al. (2013) Copyright. J Med Chem
Figure 2.1: Structures of classical antifolates including MTX, PMX, raltitrexed (RTX) and LMTX.
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Adapted with the permission of Mitchell-Ryan et al. (2013) Copyright. J Med Chem
Figure 2.2: Design of 5-substituted pyrrolo[2,3-d]pyrimidines based on structures of 6-substituted
analogs 1-4 and pemetrexed.
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In this chapter, we describe, synthesize and perform a systematical characterization of the
in vitro anti-proliferative activities and cellular mechanisms of novel 5-substituted pyrrolo[2,3d]pyrimidine antifolates (including PMX) with a benzoyl (AG124-AG129) or thienoyl (AG133AG138) rings in the side chain and one-to-six bridge carbons closely related to the 6-substituted
pyrrolo[2,3-d]pyrimidine analogs AG17, AG23, AG71 and AG94113,117207,226 (Figure 2.2). We
reasoned that the 5-substituted analogs might inhibit AICARFTase, analogous to PMX, albeit
without TS inhibition. Further, if this was accompanied by FRα and/or PCFT transport selectivity
over RFC, this would be especially appealing for targeting tumors that express high levels of these
systems.
We describe in this chapter the impact of these structural modifications on (i) transporter
specificity and (ii) the targeted pathway (TS versus de novo purine nucleotide biosynthesis),
including (iii) the extent of cellular GARFTase and AICARFTase inhibition.

Our results

document an emerging structure–activity-relationship (SAR) for the pyrrolo[2,3-d]pyrimidine
antifolates, accompanying translocation of the 6-pyrrolo[2,3-d]pyrimidine substituent to the regio
5-position, including sustained FRα cellular uptake accompanying restoration of RFC and loss of
PCFT transport activities. The 4 carbon bridge analog of the benzoyl series (compound AG127)
is unique in that it provides the strongest evidence of dual inhibition of both AICARFTase and
GARFTase exclusive of TS in tumor cells, resulting in depletion of purine nucleotides. Finally,
our results directly examine the possibility of whether AMPK activation secondary to
AICARFTase inhibition contributes to decreased proliferation of KB human tumor cells.
2.2 Biological evaluation
Transporter-selectivity for inhibition of cell proliferation by 5- and 6-substituted
pyrrolo[2,3-d]pyrimidine regioisomers. Our initial goal was to better define the SARs for
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membrane transport of pyrrolo[2,3-d]pyrimidine antifolates relating to the impact of 5- versus 6substitutions on the pyrrole ring, based on the established antitumor activities of the 6-pyrrolo[2,3d]pyrimidine-substituted compounds AG17, AG23, AG71 and AG94 with 3- and 4-bridge
carbons, respectively, 113,117,156,228 in addition to the preclinical and clinical efficacy of PMX,196 a
5-substituted pyrrolo[2,3-d]pyrimidine with a 2-carbon bridge (Figure 2.2). In our previous
studies,113,117,207,226 compounds AG17, AG23, AG71 and AG94 were efficiently internalized by
tumor cells via FRα and PCFT but not by RFC, whereas PMX was a substrate by all three
systems.113,117
Transporter specificities are exemplified by patterns of inhibition of cell proliferation
toward isogenic Chinese hamster ovary (CHO) cell models, engineered to express human RFC
(PC43-10), PCFT (R2/PCFT4), or FRα (RT16),198,205-207,220 treated with compounds AG17,
AG23, AG71 and AG94 (Table 2.1). Results are compared to those for RFC-, PCFT-, and FRnull MTXRIIOuaR2-4 (R2) CHO cells. As previously reported, 113,117,207,226 compounds AG17,
AG23, AG71 and AG94 are potent inhibitors of FR-expressing RT16 and D4 cells, and to a
lesser (albeit still potent) extent, R2/PCFT4 cells. However, compounds AG17, AG23, AG71
and AG94 were poorly inhibitory toward RFC-expressing PC43-10 and R2 cells. Compounds
AG17, AG23, AG71 and AG94 were also highly active toward KB nasopharengeal carcinoma
cells and IGROV-1 ovarian carcinoma cells, both of which express elevated FRα, along with
RFC and PCFT.220 Complete reversal of antiproliferative effects of compounds AG17, AG23,
AG71 and AG94 toward the FRα-expressing cell lines was seen in the presence of excess (200
nM) folic acid, further demonstrating that cellular uptake of these analogs are mediated primarily
via FRα, as previously reported (Table 2.1).198,207
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5-Substituted pyrrolo[2,3-d]pyrimidine analogs with a side-chain benzoyl group (analogs
of compounds AG17and AG23) and thienoyl group (analogs of compounds AG71 and AG94) with
bridge lengths from 1 to 6 carbons (compounds AG124-129 and AG133-138) were synthesized
and tested for their antiproliferative activities toward the CHO and human tumor models (Table
2.1). For the benzoyl series, the 2 carbon 5-pyrrolo[2,3-d]pyrimidine analog (compound AG125)
is structurally identical to PMX. 5-Substitutions restored RFC-directed anti-proliferative activity,
as reflected in dramatically increased anti-proliferative effects of this series toward PC43-10 cells
compared to RFC-, PCFT-, and FR-null R2 cells, in the order (numbers of bridge carbons noted in
parentheses), AG125 (2C) > AG127 (4C) ~AG126 (3C) > AG128 (5C) >> AG124 (1C) ~AG129
(6C) (benzoyl series), and AG134 (2C) ~AG136 (4C) > AG135 (3C) > AG137 (5C) >> AG133
(1C) ~ AG138 (6C) (thiophene series). Conversely, for PCFT-expressing R2/PCFT4 CHO cells,
with the exception of compound AG125 and (to a lesser extent) the thiophene analogs AG134 and
AG137, the antiproliferative effects for the 5-substituted analogs were attenuated compared to the
6-substituted analogs (e.g., for direct comparisons between paired 5- and 6-substituted analogs,
compare IC50s for compounds AG17 and AG126 and for compounds AG71 and AG135,
respectively in Table 1.1).
With the FRα-expressing sublines, potencies were also reduced for the 5-substituted
compounds, compared to 6-substituted analogs. These differences range from slight (compare
AG23 to AG127, and AG71 to AG28) to substantial (compare AG17 to AG126, AG71 to AG135,
and AG94 to AG136) (Table 2.1). In contrast to results for PCFT- and RFC-expressing cells, the
impacts of bridge lengths were distinctly different between the benzoyl and thienoyl series, with
anti-proliferative activities toward FRα-expressing RT16 CHO cells in rank order, AG127 (4C) >
AG125 (2C) > AG128 (5C) > AG126 (3C) > > AG124 (1C) ~ AG129 (6C) (benzoyl series), and
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AG136 (4C) ~ AG137 (5C) > AG135 (3C) > AG134 (2C) > AG133 (1C) ~ AG138 (6C) (thioenoyl
series). An analogous pattern of sensitivities was obtained with KB human tumor cells, and for
both the KB and RT16 cell lines, inhibitory effects were substantially reversed by 200 nM folic
acid, confirming FRα as the major uptake mechanism. While PCFT and RFC likely mediate
cellular uptake of certain analogs (e.g., AG127 and AG136), uptake by FRα appears to
predominate.
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Figure 2.3: Inhibition of RFC-mediated transport and relative FRα-binding affinities by 6(compound 2) and 5- (compound 8) substituted pyrrolo[2,3-d]pyrimidine antifolates. Panel
A: To determine if novel antifolates were able to bind human RFC and inhibit transport of
[3H]MTX, reflecting transport of the novel analogs by RFC, we used PC43-10 CHO cells
ectopically expressing human RFC but not FRs or PCFT. Uptake of 0.5 μM [3H]MTX was
measured at 37˚ C for 2 min in Hepes-buffered saline (pH 7.2), in the absence or presence of 10
µM of non-radioactive inhibitors, including compound (Cpd) AG23, AG71, AG127 or AG136, or
the classical agents, PMX and MTX. Experimental details are described in the Methods and
Materials. Internalized [3H]MTX was normalized to total cell protein and expressed as pmol/mg
protein. Transport results are compared to those for RFC-null R2 cells. Panel B: To assess the
relative binding affinities of the novel antifolates to FRα, we performed direct competitive binding
assays using [3H]folic acid (FA) in the FRα-engineered CHO cell line, RT16. RT16 cells were
washed, then incubated with Hank’s balanced salts solution containing 50 nM [3H]folic acid in the
absence or presence of unlabeled 6-pyrrolo[2,3-d]pyrimidine compounds AG23, AG71, AG127or
AG136, or folic acid, PMX, or MTX at various concentrations. Relative binding affinities were
calculated as the inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding
by 50%. By definition, the relative affinity of folic acid for FRα is 1. Further, details for the
transport and binding assays are provided in the Methods and Materials. For both series of
experiments, results are presented as mean values plus/minus standard errors from 3 experiments.
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To complement results showing anti-proliferative effects of the most potent 5-substituted
analogs, AG127 and AG136, toward PC43-10 CHO cells expressing human RFC, we measured
competitive inhibitions of [3H]MTX (0.5 µM) transport in this model over 2 minutes at 37° C
(Figure 2.3A). MTX is a well-characterized surrogate substrate for RFC and the extent of
[3H]MTX transport inhibition by competitive unlabeled (anti)folate ligands correlates with their
membrane transport by RFC.9 For our study, we compared inhibitory effects of 10 μM of
compound AG127 and AG136, to those for the corresponding 6-substituted compound AG23 and
AG71, and to PMX and MTX. Transporter-null R2 cells were used to as a measure of baseline
[3H]MTX uptake. Whereas AG23 and AG71 were poor inhibitors of [3H]MTX uptake (< 25%
inhibition), compound AG127 and AG136 were a reasonably good inhibitors (>90%), with a
inhibitory potency approximating that for PMX and net transport only slightly greater than the
very low levels recorded for R2 cells. Clearly, unlike the 6-substituted pyrrolo[2,3-d]pyrimidine
analogs, the 5-substituted compounds lack specificity for FRα and/or PCFT over RFC.
Compounds AG127 and AG136 showed anti-proliferative effects toward FRα-expressing
RT16 CHO cells and KB human tumor cells (Table 2.1). To directly demonstrate drug binding to
FRα, a prerequisite of cellular uptake by this endocytotic mechanism, we used competitive binding
assays with [3H]folic acid with RT16 cells, treated with unlabeled ligands which compete for FRα
binding16-20 (Figure 2.3B). Relative FRα binding affinities for the 5- (compounds AG127 and
AG136) versus 6-substituted (compounds AG23 and AG71) analogs paralleled their antiproliferative activities. However, this correlation did not quite extend to PMX (compound AG125)
or to MTX, indicating that multiple factors in addition to FRα binding affinities contribute to net
growth inhibition of FRα-expressing cells for these antifolates.
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A.
hRFC
Compound

hFRα

hPCFT

Structure
PC43-10

R2

RT16

RT16 (+FA)

R2/hPCFT4

R2(VC)

1-AG17

6-pyr/3C/Benzoyl

648.6(38.1)

>1000

4.1(1.6)

>1000

23.0(3.3)

>1000

2-AG23

6-pyr/4C/Benzoyl

>1000

>1000

6.3 (1.6)

>1000

213 (28)

>1000

3-AG71

6-pyr/3C/Thieno

>1000

>1000

1.82(0.28)

>1000

43.4(4.1)

>1000

4-AG94

6-pyr/4C/Thieno

101.0(16.6)

273.5(49.1)

0.31(0.14)

>1000

3.34(0.26)

288(12)

5-AG124

5-pyr/1C/Benzoyl

>1000

>1000

>1000

>1000

>1000

>1000

6-AG125

5-pyr/2C/Benzoyl

30.6 (6.2)

>1000

18.2(3.8)

>1000

22.3(8.6)

>1000

7-AG126

5-pyr/3C/Benzoyl

68.8(21.2)

>1000

72.0(27.1)

>1000

329(61)

>1000

8-AG127

5-pyr/4C/Benzoyl

56.6(5.8)

>1000

8.6(2.1)

>1000

840(90)

>1000

9-AG128

5-pyr/5C/Benzoyl

196.4 (55.0)

>1000

33.5(2.5)

>1000

>1000

>1000

10-AG129

5-pyr/6C/Benzoyl

>1000

>1000

>1000

>1000

>1000

>1000

11-AG133

5-pyr/1C/Thieno

>1000

>1000

>1000

>1000

468 (112)

>1000

12-AG134

5-pyr/2C/Thieno

59.8(11.1)

>1000

550 (50)

>1000

80.2(5.5)

>1000

13-AG135

5-pyr/3C/Thieno

116.0(22.5)

>1000

109 (44)

>1000

312 (90)

>1000

14-AG136

5-pyr/4C/Thieno

38.3(6.6)

>1000

49.3(11.5)

>1000

141(40)

>1000

15-AG137

5-pyr/5C/Thieno

243.2(49.9)

>1000

45.5(22.8)

>1000

57.4(21.4)

>1000

16-AG138

5-pyr/6C/Thieno

>1000

>1000

>1000

>1000

>1000

>1000

MTX

-

12(1.1)

216(8.7)

114(31)

461(62)

120.5(16.8)

>1000

RTX

-

6.3(1.3)

>1000

15(5)

>1000

99.5(11.4)

>1000

LMTX

-

12(2.3)

>1000

12(8)

188(41)

38.0(5.3)

>1000
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B.
hRFC/ FRα/hPCFT
Compound

Structure

KB (+Thd/Ade/
KB

IGROV-1

IGROV-1

KB (+FA)
AICA)

(+FA)

1-AG17

6-pyr/3C/Benzoyl

1.7(0.4)

>1000

Ade/AICA

--

--

2-AG23

6-pyr/4C/Benzoyl

1.9 (0.7)

>1000

Ade/AICA

3.9 (.98)

>1000

3-AG71

6-pyr/3C/Thieno

0.026(0.03)

>1000

Ade/AICA

.98 (2.0)

>1000

4-AG94

6-pyr/4C/Thieno

0.55(0.10)

>1000

Ade/AICA

--

--

5-AG124

5-pyr/1C/Benzoyl

>1000

>1000

--

--

--

6-AG125

5-pyr/2C/Benzoyl

9.94(3.11)

690 (310)

Thd/Ade

60.7 (7.1)

>1000

7-AG126

5-pyr/3C/Benzoyl

49.5(13.2)

533(233)

Ade

100 (55)

>1000

8-AG127

5-pyr/4C/Benzoyl

12.7(5.4)

700 (300)

Ade

94.3 (7.6)

>1000

9-AG128

5-pyr/5C/Benzoyl

17.3(8.9)

898(102)

Ade/AICA

--

--

10-AG129

5-pyr/6C/Benzoyl

>1000

>1000

--

--

--

11-AG133

5-pyr/1C/Thieno

>1000

>1000

--

--

--

12-AG134

5-pyr/2C/Thieno

875 (125)

>1000

--

--

--

13-AG135

5-pyr/3C/Thieno

211 (58)

825(175)

Ade/AICA

--

--

14-AG136

5-pyr/4C/Thieno

66.0(14.4)

900 (100)

Ade/AICA

29.5 (14.9)

>1000

15-AG137

5-pyr/5C/Thieno

41.7(10.1)

>1000

Ade

--

--

16-AG138

5-pyr/6C/Thieno

>1000

>1000

-

--

--

MTX

-

6.0(0.6)

20(2.4)

--

--

--

RTX

-

5.9(2.2)

22(5)

--

--

--

LMTX

-

1.2(0.6)

31(7)

--

--

--

Table 2.1: IC50s (in nM) for 5- and 6-substituted pyrrrolo[2,3-d]pyrimidine antifolates and
classical antifolates in RFC-, PCFT-, and FR-expressing cell lines. Growth inhibition assays
were performed for CHO sublines engineered to express human RFC (PC43-10), FRα (RT16), or
PCFT (R2/PCFT4), for comparison with transporter-null [R2, R2(VC)] CHO cells (A), and for the
KB human tumor subline (express RFC, FRα, and PCFT) (B), as described in the Methods and
Materials. For the FRα experiments, growth inhibition assays were performed in the presence and
the absence of 200 nM folic acid (FA). The data shown are mean values from 3-10 experiments
(plus/minus SEM in parentheses). Results are presented as IC50 values, corresponding to the
concentrations that inhibit growth by 50% relative to cells incubated without drug. Data for MTX,
RTX, LMTX, and compounds AG17, AG23, AG71, and AG94 (Figure 2.1) were previously
published (structures of these compounds are in Figure 1 whereas the structures for compounds
AG133-AG138 are shown in Figure 2.2. For KB cells, data are shown for the protective effects
of nucleoside additions including adenosine (60 µM), thymidine (10 µM), or AICA (320 µM).
Examples of these data are graphed in Figure 2.4. For the 5- and 6-pyrrolo-2,3-d)pyrimidine
compounds AG17-AG138, the structural motifs are documented, i.e., the pyrrole
substitution/bridge length/B-ring structure. The most potent compounds in the 5-substituted series
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(AG127 and AG136), along with their 6- substituted analogs (AG23 and AG71) and PMX
(AG125) were evaluated for anti-tumor activity in the human ovarian cancer cell line IGROV-1.
Undefined abbreviations: Cpd, compound; ND, not determined. The results with compounds
AG17, AG23, AG71 and AG94 were previously reported.198,204,207,226
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Inhibition of de novo purine nucleotide biosynthesis by both 5- and 6-pyrrolo[2,3d]pyrimidine compounds leads to a cytotoxic response via purine nucleotide depletion. De
novo purine nucleotide biosynthesis includes 10 reactions by which phosphoribosyl pyrophosphate
(PRPP) is converted into inosine monophosphate (IMP), the precursor of AMP and GMP (refer to
Figure 1.3 in chapter 1). There are two folate-dependent enzymes in the pathway which are
possible targets for folate-based therapies i.e., GARFTase (catalyzes steps 2, 3 and 5) and
AICARFTase (catalyzes steps 9 and 10). Previous studies established that GARFTase was the
intracellular enzyme target for LMTX183,313 and for compounds AG17, AG23, AG71 and
AG94.198,207 For PMX, TS is the primary intracellular target, although modest inhibitions of
GARFTase and DHFR were also reported.309 Most recently, AICARFTase was implicated as a
potentially important secondary enzyme target for PMX (in the presence of excess thymidine to
circumvent TS inhibition) by nucleoside protection experiments and metabolic assays.196,197
To identify the targeted pathway for 6-substituted compounds AG23 and AG71, we
previously used nucleoside protection experiments with adenosine (60 µM) and thymidine (10
µM), to distinguish de novo purine nucleotide from thymidylate biosynthesis, respectively.198,204207,220,313

To further identify the likely folate metabolizing enzyme targets in purine nucleotide

biosynthesis (GARFTase versus AICARFTase), cells were treated with the antifolates in the
presence of AICA (320 µM), which is metabolized to AICA ribonucleotide (ZMP), the substrate
for AICARFTase substrate, thus bypassing the step catalyzed by GARFTase198,204-207,220,313
(Figure 1.3).
We used this approach for KB cells treated with compounds AG125-128 and AG135AG137, with results compared to those for compounds AG23 and AG71, and to PMX (compound
AG125) (Table 2.1; Figure 2.4 shows the nucleoside protection results for PMX and compounds
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AG23 and AG71 compared to those for compounds AG127 and AG136). With compounds AG23
and AG71, both adenosine and AICA were completely protective, establishing de novo purine
biosynthesis and GARFTase as the principal targets.198,204,207 With PMX, thymidine, adenosine,
and AICA were all partially protective, albeit to different extents. Combined thymidine and
adenosine completely protected KB cells from the growth inhibitory effects of PMX (not shown).
The growth inhibitory effects of the 5-substituted compounds AG126-AG128, AG135 and 137
with KB cells were unaffected by excess thymidine but were completely reversed in the presence
of adenosine alone, indicating that exclusively de novo purine nucleotide synthesis was being
targeted (rather than combined thymidylate and purine nucleotide synthesis). Whereas AICA
alone completely protected KB cells from the inhibitory effects of compound AG128 andAG135,
AICA alone was only partially protective with compounds AG126, AG127 and AG137.
Thus, inhibition of purine nucleotide biosynthesis by compounds AG126, AG127 and
AG136 is likely a composite effect of dual inhibitions involving both GARFTase and
AICARFTase. These results strongly imply that shifting the substituent from the 6- to the 5position on the pyrrolo[2,3-d]pyrimidine ring system results in an altered inhibition of the targeted
enzymes.
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Figure 2.4: Cell proliferation assays with protection by nucleosides including thymidine and
adenosine and 5-amino-imidazole-4-carboxamide (AICA) to identify intracellular targets of
compounds AG127 and AG136. To identify the targeted pathways and the folate-dependent
intracellular enzymes in KB cells treated with compounds AG127 and AG136 (1-1000 nM), cell
proliferation assays were performed in the presence of 10 μM thymidine, 60 μM adenosine or 320
μM AICA. Relative cell numbers were measured with a fluorescence-based viability assays
(CellTiterBlue™). Results were normalized to those for untreated cells (no drug) and for
compounds AG127 and AG136, results are shown in comparison to those for PMX and compound
AG71. Details are provided in the Methods and Materials. Results shown are representative of
triplicate experiments. Analogous experiments were performed for compounds AG126 and
AG128 and the results are summarized in Table 2.1.
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Decreased purine nucleotide biosynthesis resulting from inhibition of folate-dependent

enzymes can be monitored by following changes in ATP pools, a surrogate measure of total purine
nucleotides (Figure 2.5). KB tumor cells were treated for 24 h with the novel 5-substituted analog
AG127 and AG136, or the corresponding 6-subsituted regioisomers, compounds AG23 and AG71,
respectively. A parallel incubation was performed with PMX. ATP pools were extracted and
measured by an HPLC ion-pairing method.204,314 In KB cells, following a 24 h incubation,
compounds AG127 and AG136, like AG23 and AG71, potently depleted ATP pools (>90%),
whereas PMX was much less effective (~60% inhibition).
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Figure 2.5: Compounds AG23, AG71 AG127and AG136 deplete ATP pools in KB cells. KB cells were
treated with 1 µM of the novel 5- and 6-substituted pyrrolo[2,3-d]pyrimidine antifolates AG23, AG71
AG127 and AG136 , or with PMX for 24 h. Nucleotides were extracted and analyzed by ion-pair HPLC
using a C18 column. Experimental details are in the Methods and Materials. Results are presented as mean
values +/- standard errors.
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Inhibition of de novo purine biosynthesis by compound 8 results in cytotoxicity and
apoptosis. To confirm that depletion of purine nucleotides by the most potent 5-substituted
analog, compound AG127, results in cytotoxicity toward KB cells, we performed colony-forming
assays. In these experiments, KB tumor cells were treated with various concentrations (1-10 µM)
for 48 h, then washed and plated without drug. Colonies were enumerated after 10 days (Figure
2.6A). Following drug exposures, inhibitory effects of compound AG127 were irreversible with
complete loss of colony formation at the highest drug concentrations, thereby establishing
compound AG127 as cytotoxic.
Programmed cell death type I (mitochondrial pathway) requires ATP to form the death
complex with cytochrome C and caspase 9 and to carry out other energy-requiring processes for
enzymatic degradation and modification of cellular components.315 Previous studies suggested
that the 6-substituted pyrrolo[2,3-d]pyrimidine antipurine antifolate AG17 was capable of
inducing apoptosis, albeit less than that indicated by daunorubicin over 24 h.198 Additional
experiments were performed with KB cells treated with compound AG127 to assess its effects on
cell cycle progression and induction of apoptosis, with comparisons to PMX and compound AG23.
Cells were exposed to 1 µM drugs for 48 or 96 h. Cultures were then divided, with one fraction
fixed and stained with propidium iodide (PI) for flow cytometry analysis of cell cycle distribution
(Figure 2.6B). An additional fraction was assayed for apoptosis by flow cytometry with annexin
V/fluorescein isothiocyanate (FITC) /7-amino actinomycin D (AAD) staining (Figure 2.6C).
At 48 h, minimal effects on the cell cycle were observed, except for PMX, which induced
a G1/Go-phase arrest relative to the untreated (DMSO) control (data not shown). At 96 h, all
compounds tested increased the percentages of cells in S-phase (albeit to different extents), while
reducing those in the G1/Go- and G2/M-phases of the cell cycle. The histograms display a change
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in DNA content in cells treated with AG23 and AG127, suggesting aneuploidy. A prominent
increase in the sub-G1 population at 96 h was also seen (Figure 2.6B; most notable for compounds
AG23 and AG127), indicating apoptosis was induced.
Annexin V-FITC staining was used to further monitor induction of apoptosis.

For

compounds AG23 and AG127, as well as PMX, positive annexin V-FITC staining increased over
time (results for 96 h are shown in Figure 2.6C, with distinct increases in both early (annexin-VFITChigh/7-AADlow) and late apoptotic fractions (annexin-V-FITChigh/7-AADhigh), compared to
those for the untreated (DMSO) control (i.e., the fractions of cells in early apoptosis were 33.8%
and 0.49% for compound AG127-treated and control cells, respectively, whereas the fractions in
late apoptosis at 96 h were 26.7% and 2.1%, respectively). Nearly identical results were obtained
with compound AG71, although for PMX, the distribution between the early and late apoptotic
fractions was somewhat different. Thus, the 5- and 6-substituted pyrrolo[2,3-d]pyrimidines AG23
and AG127 can induce apoptosis, resulting in cell death in spite of depleted ATP pools.
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Figure 2.6: Inhibition of de novo purine biosynthesis by compound AG127 results in
cytotoxicity and apoptosis. Panel A. KB cells (1000 cells) were treated with compound AG127
(0.5 to 10 µM) for 48 h, after which cells were washed (3x) and complete drug-free medium was
added. Colonies were allowed to grow for 10 days, at which time they were stained with methylene
blue and counted. Results are presented as mean values +/- standard errors from 3 experiments.
Panel B: Cell cycle analysis. KB cells were treated with 1 µM antifolates (PMX, compound
AG23, compound AG127) for 96 h, washed, then fixed and stained with PI. Cell cycle
distributions were analyzed by flow cytometry. The sub-G1 fraction (white fill) increased from
3.52% in the absence of drugs upon treatment with PMX (17.3%) or compounds AG23 (45.1%)
or AG127 (36.7%). For the non-sub-G1 population, the cell cycle distributions [colors are green
for G1/G0, yellow for S, and blue for G2/M] are as follows: no additions, 67.4% G1/G0, 15.9% S,
13.2% G2/M; PMX, 47.8% G1/G0, 27.5% S, 7.46% G2/M; compound AG23, 22.3% G1/G0, 31.4%
S, 1.18% G2/M; and compound AG127, 12.9% G1/G0, 48.2% S, 2.31% G2/M. Panel C: Analysis
of apoptosis by annexin V-FITC/7-AAD staining and flow cytometry are shown for KB cells
treated with PMX, or with compounds AG23 or AG127 for 96 h. Results are compared to those
for controls treated with DMSO in lieu of drug. The percentages of cells in each quadrant [viable
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cells (annexin V-FITClow/7-AADlow;Q4), early apoptosis (annexin V-FITChigh/7-AADlow;Q3), and
late apoptosis/necrosis (annexin V-FITChigh/7-AADhigh;Q2) are summarized. These experiments
were ran with the assistance of Dr Eric Hales who performed the data analysis.
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Dual Inhibition of GARFTase and AICARFTase by 5-substituted pyrrolo[2,3d]pyrimidine antifolates and downstream effects of accumulated ZMP on AMPK as
mechanisms resulting in cytotoxicity.

Experiments were performed to measure cellular

GARFTase activity in KB tumor cells treated with the 6- (compounds AG23 and AG71) and 5substituted (compounds AG127 and AG136, and PMX) pyrrolo[2,3-d]pyrimidines. For this
purpose, we used an in situ activity assay for GARFTase which measures incorporation of
[14C]glycine into [14C]formyl GAR in the presence of azaserine over 16 h.147,153-156,168,233
Cells were harvested, washed with PBS and treated with trichloroacetic acid (TCA). Following
deproteinization, acid-soluble metabolites were ether-extracted and fractionated by ion-exchange
chromatography, permitting isolation and quantitation of [14C]formyl GAR. Both 5- and 6substituted analogs exhibited a dose-dependent decrease in [14C]formyl GAR. Compound AG71
was the most potent of the analogs tested in contrast to its 5-substituted analog, compound AG136,
which was the least. However, compound AG23 was more potent than either PMX or compound
AG127, with an IC50 for this compound exceeding those for 5-substituted compounds by 2- to 5fold (Figure 2.7).
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Figure 2.7: In situ GARFT assay. GARFT activity and inhibition by 5- and 6-substituted
pyrrolo[2,3-d]pyrimidine analogs, AG23, AG71, AG127, AG136 and PMX were evaluated in situ
with KB cells. KB cells were treated with drugs in the presence of 4 µM azaserine. [ 14C]glycine
and L-glutamine were added and cells were incubated for 16 h at 37oC. Radioactive metabolites
were extracted and fractionated on 1 cm columns of AG1 x 8 (Cl-); the fractions were collected
and determined for radioactivity. Accumulation of [14C]formyl GAR was calculated as a percent
of vehicle control over a range of antifolate concentrations. Results are presented as mean values
± standard errors from 3 experiments. IC50s are summarized in the table. Details are described in
the Methods and Materials.
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The anti-proliferative effects of PMX independent of its impact on TS were previously
attributed to its inhibition of AICARFTase in addition to GARFTase, as reflected in incomplete
protection by AICA in the presence of thymidine, and the accumulation of the AICARFTase
substrate ZMP in tumor cell lines treated with PMX, as measured by anion-exchange HPLC
analysis.196,197 ZMP accumulation showed both dose- and time-dependence for PMX and resulted
in activation of AMPK via its role as an AMP mimetic and suppression of mTOR.
To validate the findings from our AICA protection experiments with lead 5-substituted
analog, compound AG127 (Figure 2.4), and to explore whether AICARFTase is a bona fide target
for the novel 5-substituted pyrrolo[2,3-d]pyrimidine AG127, analogous experiments were
performed to measure accumulation of ZMP in KB cells treated with 1 µM of compound AG127
or PMX, as a measure of AICARFTase inhibition. ZMP accumulated in a linear fashion for up to
48 h in KB tumor cells for both compounds (not shown), with PMX showing approximately 2fold increased levels over compound AG127 (Figure 2.8A).
To verify the impact of ZMP accumulation on AMPK phosphorylation in KB cells treated
with compound AG127 or with PMX, western blot analysis was performed of total and
phosphorylated AMPK in KB cells treated with these antifolates for 48 h, compared to levels of
phospho-AMPK resulting from treatment with established AMPK activators including AICA,
AICA ribonucleoside, and metformin316 (Figure 2.8B). Although KB cells are LKB1-null (the
principal upstream kinase responsible for phosphorylating AMPK), AMPK is still activated upon
treatment with known AMPK activators. While AMPK is activated by PMX, compound AG127
was not significantly activating despite the accumulation of ZMP. Interestingly, neither AICA
(not shown) nor metformin (data not shown) at concentrations found to activate AMPK were
growth inhibitory toward KB cells.
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Reprinted with permission of Mitchell-Ryan et al.221 Copyright (2013) J Med Chem
Figure 2.8: Accumulation of ZMP by 5-substituted pyrrolo[2,3-d]pyrimidines PMX, and
compound AG127. Panel A: ZMP (AICA ribonucleotide) accumulation was measured in KB
cells treated for 48 h with the 5-substituted pyrrolo[2,3-d]pyrimidine antifolate AG127, or PMX.
Methods for extracting nucleotide metabolites and for measuring ZMP levels by ion-exchange
HPLC are detailed in the Methods and Materials. Panel B: KB cells were treated at indicated for
48 h, followed by western analysis of phosphorylated AMPK on a 4-20% gradient gel. Blots were
probed with antibodies to phospho- and total AMPK, and to β-actin.
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2.3 Discussion
The development of rationally designed cytotoxic antifolates remains an area of significant
interest to anticancer drug development, as exemplified by the relatively recent approval of
PMX317 and pralatrexate318 for cancer, more than 50 years since introduction of MTX.319
Unfortunately, the ubiquitous presence of RFC may contribute to unwanted toxicities of these
classical antifolates toward normal tissues. Based on this, growing attention has focused on
developing novel folate-based compounds with tumor targeting premised on transport selectivity
for FRs or PCFT over RFC,75,198,204-207,220 a pursuit that until recently175 continued to be challenged
by the lack of structural information on the major folate transport systems.
The antitumor efficacy for the 5-substituted 2-carbon bridge pyrrolo[2,3-d]pyrimidine
PMX reflects its cellular uptake by all the major folate transport systems.147,153-156 While the
corresponding 6-substituted analog of PMX was pharmacologically inert, with increasing bridge
lengths, 6-substituted pyrrolo[2,3-d]pyrimidines were surprisingly potent inhibitors of cell
proliferation, although membrane transport by RFC was lost.204,320

The 6-pyrrolo[2,3-

d]pyrimidine benzoyl analogs with 3 and 4 bridge carbons, compounds AG17 and AG23,
respectively, were the most active of this series, reflecting their FR and PCFT cellular uptake, with
little to no transport by RFC, and their potent inhibitions of GARFTase, the first folate-dependent
step leading to the synthesis of IMP.153,237 Inhibition of de novo synthesis of purine nucleotides
resulted in ATP depletion, leading to cytotoxicity and apoptosis.153,237
In this report, our goal was to further establish a comprehensive SAR for the 5- versus 6substituted pyrrolo[2,3-d]pyrimidine ring system in relation to folate transporter specificity and
inhibition of intracellular targets, based in part on findings of transporter promiscuity for
PMX,198,204-207 and reports that PMX may in part derive its antitumor effects by inhibiting
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AICARTase, resulting in accumulation of ZMP and activation of AMPK in addition to inhibiting
TS. 145,146 Compared to the 6-substituted analogs, we found that the 5-substituted compounds in
general: (i) were better substrates for RFC with the highest antiproliferative activities for
compounds with 2-4 bridge carbons independent of the nature of the side chain ring system; (ii)
were poorer substrates for PCFT with the exception of the 2-carbon bridge compound, PMX
(AG125); and (iii) preserved FR cellular uptake, with the 4-carbon bridge analog AG127 showing
the greatest FRα selectivity and potency in this expanded 5-substituted series of analogs without
TS inhibitory activity.
Compound AG127 was cytotoxic, as reflected in loss of clonogenicity in KB cells, and
effected S-phase accumulation and apoptosis over 96 h.

Like its 6-substituted counterpart

compound AG71,204 compound AG127 resulted in ATP depletion, although this appeared to be
only partly due to inhibition of GARFTase. Rather, a unique feature of the 5-substituted analog
AG127 relates to its dual inhibition of both the GARFTase and AICARFTase reactions in de novo
purine biosynthesis. While PMX also inhibits GARFTase, the finding that the AICARFTase
substrate ZMP accumulates in the presence of this drug suggested that GARFTase inhibition must
be incomplete and that AICARFTase must also be a target as previously described, 145,146 although
for PMX, total purine nucleotides, as reflected in ATP pools, were significantly preserved.
Compound AG127, also inhibited AICARFTase, as reflected in incomplete protection in cell
proliferation assays by AICA and demonstrated accumulation of the AICARFTase substrate ZMP,
albeit less than for a comparable concentration of PMX.
Previous studies suggested that AMPK activation secondary to ZMP accumulation and
AICARFTase inhibition may result in inhibition of mTOR and contribute to the antitumor effects
of high levels of PMX in the presence of thymidine.196,197 In the present study, we used KB human
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tumor cells treated with PMX or with compound AG127. In this LKB1-deficient tumor cell line,
ZMP accumulation was accompanied by AMPK activation in the presence of PMX but not
compound AG127. Robust AMPK activation was also seen upon treatment with AICAR, or
metformin. However, ZMP accumulation and AMPK activation did not appear likely to contribute
to the anti-proliferative effects of PMX in KB cells, as neither AICA nor metformin inhibited cell
proliferation. The antiproliferative and cytotoxic effects of compound AG127 toward KB cells
must derive from a depletion of ATP pools, secondary to inhibition of both GARFTase and
AICARFTase, rather than from activation of AMPK.
In summary, a series of classical 5-substituted pyrrolo[2,3-d]pyrimidine antifolates
AG124-AG129 were designed and synthesized as a hybrid of PMX and 6-substituted pyrrolo[2,3d]pyrimidines AG17, AG23, AG71 and AG94. Compound AG127, the lead compound of this
series, has an IC50 =12.7 nM against KB tumor cells in culture. Rather than only targeting
GARFTase, as with AG17 and AG23, both GARFTase and AICARFTase were identified as the
intracellular targets of AG127. The unique dual GARFTase and AICARFTase inhibition of
compound AG127 makes it an excellent lead compound for further study including the design of
additional antitumor analogs to optimize cellular folate uptake selectivity by FRs and inhibition of
folate metabolizing enzymes, leading to a new generation of potent tumor-targeted agents. The
dual inhibition of both GARFTase and AICARFTase results in potent inhibition of purine
biosynthesis and could preserve antitumor activity in the event that tumors become resistant due
to alterations in one or the other targeted enzyme. Such dual targeted inhibitors would seem to
have substantial advantages over currently used agents that principally target only one intracellular
enzyme target.
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2.4 Materials and methods
Reagents for biological studies. [3’, 5’, 7-3H]MTX (20 Ci/mmol), [3’, 5’, 7, 9-3H] folic
acid (25 Ci/mmol), and [14C(U)]-glycine (87mCi/mmol) were purchased from Moravek
Biochemicals (Brea, CA). Unlabeled folic acid was purchased from the Sigma Chemical Co. (St.
Louis, MO). LCV [(6R,S) 5-formyl tetrahydrofolate] was provided by the Drug Development
Branch, National Cancer Institute, Bethesda, MD. The sources of the antifolate drugs were as
follows: MTX, Drug Development Branch, National Cancer Institute (Bethesda, MD); and PMX
(Alimta) (LC Laboratories, Woburn, MA). Other chemicals were obtained from commercial
sources in the highest available purity. Novel antifolates (denoted by AG17-138 (see Table
2.1))221 were synthesized by Dr. Aleem Gangjee and colleuges at Duequesne University, Pittsburg
Pennsylvania.
Cell culture. MTXRIIOuaR2-4 (referred to as R2) is a RFC, PCFT and FRα null Chinese
Hamster (CHO) cell line that was a gift from Dr. Wayne Flintoff (University of Western
Ontario).321 From this parental cell line, RFC, PCFT and FRα were transfected in to give rise to
isogenic CHO cell lines designated PC43-10 (expresses RFC but not PCFT or FRα), R2/PCFT4
(expresses PCFT) and RT16 (expresses FRα).198,204-207,220,322

The CHO sublines were all

maintained in α-minimal essential medium (α-MEM) supplemented with 5% penicillinstreptomycin solution, 2 mM L-glutamate

and 10% heat-treated bovine calf serum (BCS)

(Invitrogen). Transfected cell lines were cultured in the presence of 1.5 mg/ml G418. CHO cell
lines were cultured prior to cell viability experiments in folate-free RPMI (FF-RPMI) (Invitrogen)
with dialyzed fetal bovine serum (DFBS) (Invitrogen) supplemented with 5% penicillinstreptomycin and L-glutamate. Human FRα-expressing KB (nasopharyngeal) and IGROV-1
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(ovarian) carcinoma cells were continuously maintained in FF-RPMI complete with 10% fetal
bovine serum (FBS) and 5% penicillin-streptomycin and L-glutamate.
Cell viability assays were performed exactly as previously described.198, 193-196 Cell lines
were treated with a range of concentrations of standard or novel antifolates (0-1 μM), metformin
(0-10 mM) or AICA (0-2 mM) in a 96 well plate with in FF-RPMI complete with DFBS, and 2
nM (RT-16, KB, IGROV1) or 25 nM LCV (R2/PCFT4), penicillin –streptomycin and L-glutamate
over a 96 h incubation period at 37◦C with 5% CO2. To confirm FRα-mediated drug uptake and
growth inhibition, 200 nM folic acid was added to the incubations with drug. For proliferation
assays with PC43-10 cells, cells were cultured in standard RPMI1640 with DFBS, penicillinstreptomycin and L-glutamate for 96 h. To quantitative viable cells, media was removed and Cell
Titer-blue™ fluorescent reagent (Promega) was added. Relative cell numbers were determined by
relative fluorescence units measured with a fluorescence plate reader at 590 nm emission and 560
nm excitation with Softmax Pro plate reader software. IC50 values, corresponding to the drug
concentrations that resulted in 50% loss of cell growth, were calculated from dose-response curves
using Sigma Plot (v.12) software.
In order to identify the targeted pathways/folate-dependent enzyme by the classic and
targeted antifolates, proliferation assays were performed in the presence of adenosine (60 μM),
thymidine (10 μM), or AICA hydrochloride (320 μM) and results compared to incubations in
parallel without drug additions.198,205,220
Colony forming assays were performed with compound AG127 to verify a cytotoxic (as
opposed to cytostatic) response. KB cells (~500) were plated in 60 mm dishes in FFRPMI/DFBS
supplemented with 2 nM LCV for a 24 h incubation period at 37◦C in the presence of 5% CO2.
Concentrations ranging from 0-10 μM of compound AG127 were added to media for an additional
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24 h, after which the media was aspirated and replaced with FFRPMI/DFBS supplemented with 2
nM LCV for 8-10 days. To visualize colonies, the cells were washed (2x) with room temperature
Dulbecco’s phosphate-buffered saline (PBS) (Sigma), followed by a wash of 5% trichloroactetic
acid (TCA). The TCA was removed, 10 mM borate buffer (pH 8.8) was added, followed by a 30
min incubation with 1% methylene blue in borate buffer at room temperature. The cells were was
three times with borate buffer and the stained colonies were counted.
Competitive MTX transport assays. To determine if novel antifolates bound to RFC,
reflecting membrane transport by this mechanism, competition with [3H]MTX for cellular uptake
was measured in PC43-10 CHO cells.198,207 PC43-10 cells (~1.5x106 cells) were seeded in 60mm
dishes. After 48 h, cells were washed with PBS and uptake of [3H]MTX (0.5 μM) was measured
in Hank’s Balanced Salts Solution for 2 minutes at 37◦C. Cold (~4◦C) PBS was used to quench
the reactions. Cells were washed with ice-cold PBS (3X), then solubilized with 0.5N NaOH. The
cellular homogenates were assayed for radioactivity with a scintillation counter; protein
concentrations were measured with Folin-phenol reagent.203 Levels of drug uptake were expressed
as pmol/mg cell protein.
FRα affinity binding assay. To determine the binding affinity of novel antifolates to
FRα,198 FRα-expressing RT16 CHO cells (~1.5 x106) were seeded in a monolayer with complete
α-MEM media. Cells were washed with ice-cold PBS, followed by an cold acetate buffer (10 mM
sodium acetate, 150 mM NaCl, pH 3.5) to release FRα-bound folates, then neutralized with icecold Hepes-buffered saline (HBS) (20 mM Hepes, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2 , 5
mM glucose, pH 7.4). Cells were then incubated at 0◦C for 15 min in a cocktail containing [3’, 5’,
7’,9- 3H]folic acid, in the absence or presence of unlabled folic acid or novel antifolate compounds
(0-1 μM). Cells were washed with cold HBS and solubilized with 0.5 N NaOH. The cell
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homogenates were collected and analyzed for radioactivity using a liquid scintillation counter.
Protein concentrations were measured with the Folin-phenol reagent. Bound [3H]folic acid was
expressed as pmol/mg protein. Using Sigma plot (v.12) software, dose-response curves were
created and IC50’s were calculated. Relative binding affinities were calculated as the inverse molar
ratios of unlabeled ligands require to inhibit [3H]folic acid by 50% as determined graphically with
Graphpad (v. 6.0) software. By definition, the relative affinity of folic acid is 1.
HPLC detection of ATP.

Intracellular ATP concentrations were determined using

nucleotide extractions and an HPLC method, exactly as previously described.204,314 Briefly, KB
cells were seeded in a T75 flask with FF-RPMI with 10% DFBS, 5% penicillin-streptomycin, 2
mM L-glutamine and 2nM LCV. Cells were treated with 1 µM of PMX, or compounds AG23,
AG71, AG127 or AG136 for 24 h. After the incubations cells were trypsinized and washed with
cold PBS. Nucleotide pools were fractionated on by reversed-phase HPLC on a C18 column for
determination of ATP pools.
Apoptosis and cell cycle analysis.

KB cells were treated with 1 µM of PMX of

compounds AG23 or AG127 24, 48, 72 and 96 h in FF-RPMI media complete with 10% DFBS
and 5% penicillin-streptomycin and 2 nM LCV. Harvested cells were trypsinized and washed with
cold PBS. Samples were equally divided so cells could be stained with PI for cell cycle analysis
and with Annexin V/7-AAD (Beckman) for apoptosis assays. For cell cycle analysis, cells were
fixed with cold ethanol (added drop-wise), then resuspended and stained in PBS containing 50
µg/mL PI and 100 µg/mL RNAse (type I-A) (Sigma). Cell populations were analyzed by flow
cytometry and Flowjo software.

Flow cytometry and Flowjo software were also used to

discriminate positively stained Annexin V/7-AAD populations including viable (annexin V and 7-
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AAD negative), early apoptotic (annexin V positive/ PI negative or 7-AAD low), and late
apoptotic/necrotic (annexin V positive/PI positive or 7-AAD high).
In situ GARFT inhibition assays. To measure the extent of intracellular GARFT
inhibition in the presence of antifolate inhibitors, we examined the metabolic incorporation of
[14C(U)] glycine into [14C]formyl GAR (Figure 2.4) in the presence of azaserine.
previously published methods,

147,153-156,168,233

Using

KB cells were seeded in complete media (above)

and allowed to adhere to substratum for 24 h. Cell were then washed with FF-RPMI, L- glutamine
free with 10% DFBS, 5% penicillin-streptomycin and 2 nM LCV. Cells were incubated at 37⁰C
with 5% CO2 for 1 h with folate- and L-glutamine-depleted media containing 2 nM LCV, with and
without PMX and compounds AG23, AG71, AG127, or AG136 (in DMSO) over a range of
concentrations. Control cells were treated with DMSO of equal volume. Azaserine (4 µM final
concentration) was added to the cells and allowed to incubate for 30 minutes. This was followed
by the addition of L-glutamine (2 mM) and [14C(U)]glycine (final specific activity 0.1 mCi/L).
Cells were incubated 16 h. Cells were washed with ice-cold PBS, trypsinized and collected. Cells
were washed with cold PBS, then treated with 5% TCA at 0⁰C. Samples were centrifuged (4oC,
14,000 rpm) and the protein precipitants were solubilized with 0.5 N NaOH for quantitation of
protein concentrations with the Folin-phenol protein method.323 The supernatants were collected
and extracted with cold ether. After evaporation of ether, the remaining aqueous layer was gravity
filtered through a 1 cm polypropylene chromatography column (Bio-rad) of AG1x8 (chloride
form). The columns were washed with 10 mL 0.5 N formic acid, followed by 4 N formic acid (10
ml), and finally eluted with 8 ml of 1 N HCL collected in 8 fractions. The eluate was measured
for radioactivity and based on the percentages of radioactivity in the [14C]formyl GAR and non-

105

specific radioactivity, the results calculated as pmol/mg protein.

Data were graphed using

Sigmaplot (v.12) and IC50 were calculated.
HPLC detection of ZMP pools. Methods for detecting ZMP in KB cells treated with
drugs were based on those described by Rascanelli et al.196 Briefly, KB cells were treated with
assorted drugs (PMX, compound AG127 or drug free) for 48 h in FF-RPMI with 10% DFBS, 5%
penicillin-streptomycin, 2 mM L-glutamine, and 2 nM LCV. Cells were washed with PBS, treated
with ice-cold 5% TCA and proteins were precipitated by centrifugation (1600 rpm, 10 min). The
soluble fractions were extracted with ether (2x) and fractionated by ion-exchange HPLC on a SAX
250 x 2 mm column (Phenomenex) with a linear gradient from 5 mM NH4H2PO4 (pH 2.8) to 750
mM NH4H2PO4 (pH 3.9) over 25 min at a flow rate of 0.2 mL/min. Absorbance was monitored at
280 nm and the intracellular ZMP concentrations were established by fitting the peak absorbances
to a standard curve with commercial ZMP. AraCMP was used as an internal control.
Western blot analysis. KB cells were treated for 48 h with PMX or compound AG127 in
the presence of thymidine (5.6 µM). Controls include vehicle control (water or DMS0; results
were identical), or known activators of AMPK including metformin (10 mM), AICA (320 µM or
1 mM), or AICA ribonucleoside (1 mM). Cells were washed, suspended in 10 mM Tris-HCl (pH
7.0) plus proteolytic and phosphatase (Phosphostop) inhibitors (Roche Applied Science) and
disrupted by sonication. Samples were centrifuged (14,000 rpm, 10 min) and 90 µg protein
fractionated by SDS polyacrylamide gel electrophoresis on Laemmli gradient gels (4-20%).324
Proteins were electrotransferred to polyvinylidene difluoride (PVDF) membranes (Pierce).325
Detection of immunoreactive AMPK was with rabbit total and phospho-AMPK antibodies (Cell
Signaling) and IRDye800-conjugated secondary anti-rabbit antibody (LI-COR, Lincoln, NE)
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using an Odyssey® infrared imaging system (LI-COR, Lincoln, NE). β actin was detected with
anti-β actin mouse antibody and IRDye800-conjugated secondary anti-mouse antibody (LI-COR).
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CHAPTER 3: DISCUSSION
We are upon a major paradigm shift that has altered our view of ovarian cancer. With this
shift in thinking, changing the strategies in how we treat this disease is not only appropriate but
the next logical step in disease intervention. Currently, the treatment of this disease remains
unaltered from the standard agents, irrespective of the diverse molecular biology of the tumor. The
identified molecular markers should be used to determine appropriate targeted therapy to address
the driving oncogenic mechanism of the tumor. Armed with the knowledge of the precise
molecular pathways involved in the 2 categories of EOC (type I and type II), we can customize
and design novel therapeutic strategies that may prove to be more beneficial than the non-specific
chemotherapy that is currently in use.
Combination therapy has proven to be effective in the treatment of many malignancies.326
Mathematical models predict that combination therapy will be more successful at disease
eradication than single agent or adjuvant treatment because combination treatment is more likely
to prevent drug resistance.327 A treatment with a reduced propensity to drug resistance is highly
desirable in ovarian cancer, as the recurrent drug resistant tumors are difficult to treat and are
principally responsible for the patient’s demise.328 A recent study examined the effectiveness of
combining PMX with simvastatin ( a statin) in mesothelioma and lung cancers and reported an
enhanced apoptotic response with combination treatment than with single agent therapy.329 There
is a heighten interest in the use of statins as anticancer agents which stems from their ability to
disrupt the mevalonate pathway.329-335 This pathway has been associated with cell signaling, cellcycle progression, protein synthesis and membrane integrity.330 This study may serve as a platform
to encourage more studies examining the effectiveness of antifolates in conjunction with other well
established anticancer therapies (in addition to statins which are currently in their experimental
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infancy as antineoplastics) that possess a different mechanism of action. Combination therapy
may have great significance in malignancies like ovarian cancers that harbor a number of mutations
in kinases, GTPases and receptors for which there are experimental and well establish targeted
therapies. For example a FRα targeted therapy may pair with inhibitors of AKT, K-RAS, or HER2,
as many ovarian tumors have activating mutations or overexpression of these kinases GTPases and
receptors.336
Overwhelming evidence suggests that FRα confers a growth advantage to malignant
cells.60,62,128,174 There is speculation that the use of DNA damaging agents, like platinum-based
therapies, may enhance FRα expression to increase intracellular folate levels to encourage an up
regulation of nucleotide production to assist in DNA repair to address drug induced damage.263
These identified molecular events in ovarian cancer offer an opportunity for the continued growth
of the next generation of FRα-targeted treatments. To date, classic antifolates have not made a
notable appearance in the treatment of ovarian cancer. In light of the enhanced expression of FRα
driven by the use DNA damaging agents, like those used in ovarian cancer, FRα targeted
antifolates can be useful as a second line therapeutic in this disease. PMX, which shows some
affinity to FR is currently being evaluated as a treatment option in platinum resistant ovarian
cancer.337,338
3.1 Targeting the AMPK/mTOR pathway
We have characterized a novel class of agents that are effective against a cell culture model
of HGSC, endometroid carcinoma and clear cell carcinoma. Prior to obtaining crystallographic
information pertaining to FRα, rational drug design aided in determining structural elements
required for FRα-mediated drug uptake. One unique feature of the agents under investigation is
their ability to act as dual inhibitors of GARFTase and AICARFTase. This ability to inhibit
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AICARFTase, led to an accumulation of a purine intermediate (ZMP) but not AMPK activation.
Therefore this study also allowed us to review the potential significance of AMPK activation in
ovarian tumors and the potential of indirectly targeting AMPK and mTOR signaling for therapeutic
advantage. In recent years, AMPK-targeting in cancer treatment has become en vogue. Much of
its popularity can be attributed to the antidiabetics metformin and phenformin and their association
with antitumor activity and reports suggesting that type 2 diabetics taking metformin had better
cancer treatment outcomes than those taking other antidiabetics.339 While there has been much
excitement surrounding the antitumor effects metformin has displayed in breast and ovarian cancer
studies, the mechanism of action of this drug remains unclear.339-346 Most of this uncertainty arises
from metformin’s ability to induce these antiproliferative and anti-tumor effects in an AMPKdependent or -independent manner.345,347 This leaves one to question if the effect on the cellular
energy balance (AMPK/mTOR) has greater impact on cell viability than the antidiabetic is
affecting the insulin metabolism of the tumor which is causing growth suppression and or
apoptosis.
There are a number of studies that imply that AMPK activation may assist in the survival
and growth of select tumors (e.g., prostate cancer) through the activation of macroautophagy,
which in certain cellular contexts can lead to cell death or cell survival.348 Autophagy is a common
pathway for cell survival in many malignancies. The modulation of macroautophagy in autophagy
competent cells may result in no significant consequence for such cells. A recent study showed
that an apoptotic response to pemetrexed in combination with simvastatin can be enhanced in
MPM and lung cancer cells when autophagy is inhibited.332 This demonstrates that autophagy
inhibition can be an effective strategy to further potentiate cell death. In the case where FRα is the
sole means of drug transport, the method in which autophagy is inhibited becomes critical. Folate
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receptors require acidification of the lysosome to release substrate. Many pharmacologic tools
used to inhibit autophagy involve agents that prevent acidification of lysosomes and similar
organelles, thus also making FRα-mediated uptake ineffective. ATG siRNAs are useful molecular
tools in an experimental setting; however, the use of such tools in a clinical setting, to date, may
be impractical. With the growing number of chemotherapeutics that are now being identified as
AMPK activators, a closer examination of the effects of this activation should be conducted on the
tumor of question prior to the selection of therapy.
3.2 Targeting AICARFTase
This study sought to describe the significance of AICARFTase inhibition in de novo purine
synthesis in FRα-positive tumor cells. Eukaryotic AICARFTase is a bifunctional protein that
participates in formylation and cyclization to produce the purine precursor molecule IMP.349-352
Like GARFTase, AICARFTase is a critical player in the de novo production of purine nucleotides
and therefore has been suggested as a viable target to disrupt the purine biosynthetic pathway.
Although both GARFTase and AICARFTase are transformylases in the same pathway and can use
the same folate co-factor to perform their activities, they share no sequence homology.351,353 This
divergence in sequence would make a drug directed to target one enzyme highly unlikely to behave
as a substrate for the other.351 For this reason, MTAs like MTX (primary target DHFR)and PMX
(primary target TS) are rather unique because they can inhibit both enzymes.349
There are no known clinically investigated antifolates that primarily target AICARFTase.
Burroughs and Wellcome designed and produced two antifolates, BW1540 and BW2315, to
selectively target AICARFTase. These two novel agents are sulfamido bridged 5,8 dideazafolate
analogs, that were designed to create a stronger interaction between the protein and the small
molecule.351 Both analogs were reported to exhibit strong inhibition towards AICARFTase
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(BW1540, 8nM; BW2315, 6nM) as well as antitumor activity against human colon cancer cells (
BW1540 0.7-3.0µM; BW2315 1.0-5.0µM).351 Other non-folate based AICARFTase inhibitors,
326203-A (2, -[5 hydroxy-3-methyl-1-1(2 methyl-4-sulfophenyl0-H-pyrazol)-4 sulfo-benzoic
acid) have been explored, however none of these novel analog have progressed to clinical
studies.353
Experiments performed by the Moran lab with PMX prompted our own investigation using
5-substituted pyrrolo[2,3-d]pyrimidines that indirectly suggested inhibition of the enzyme. Direct
quantitation of enzyme inhibition may help to elucidate a role in AICARFTase targeting for the
disruption of de novo purine synthesis. Using the structural information for both FRα and the
AICARFTase enzyme may bring us closer to designing an FR directed inhibitor.
This body of work includes the characterization of novel potent 5- and 6-substituted pyrrolo
[2,3-d] pyrimidines that are effective against in vitro model of HGSC, endometroid carcinoma and
clear cell carcinoma (IGROV-1). Approximately 90% of advanced stage ovarian cancers are
HGSC as this subtype generally presents at an advanced stage.232,247 Patients who present in stages
III-IV have a 5 year survival rate of 15-30% and generally succumb to complications associated
with this disease. The grim statistics of ovarian cancer prompt the clinical development of highly
potent compounds with reduced toxicity to allow for treatment at longer intervals to achieve
maximum efficacy. We can learn from the failure of the folic acid-conjugated toxin, vintafolide,
and design improved folate-based cytotoxins akin to the novel compounds outlined in the study.
The novel compounds examined in these studies are excellent candidates for further
development. Pharmacokinetic data and orthotropic mouse models of EOC may enhance and aid
in greater support of these analogs as lead compound for more extensive pre-clinical and clinical
investigations. All together, we have developed agents with tumor selectivity based on an inherent
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loss of purine salvage abilities due to the deletion of MTAP and their overexpression of FRα. FRαpositive tumors treated with novel 6- substituted pyrrolo[2,3-d]pyrimidines will undergo cell death
due to purine nucleotide depletion via GARFTase inhibition. Such depletion results in a reduction
of cellular ATP pools, an induction of cell cycle arrest and eventually apoptosis. The 5- substituted
pyrrolo[2,3-d]pyrimidines share the unique characteristic of acting as a dual inhibitor of both
AICARFtase and GARFTase, albeit the potency of inhibition towards GARFTase is reduced.
While the 5-substituted analogs were able to induce ATP depletion, cell cycle aberrations and
apoptosis, despite ZMP accumulation (likely resulting from AICARFTase inhibition) they were
unable to activate AMPK. The accumulation of ZMP alone, independent of AMPK activation
may have been sufficient to initiate a cytotoxic response. There are a number of studies that
suggest that ZMP is a toxic metabolite with many cellular targets in addition to AMPK.354-356 ZMP
accumulation has been linked to mitochondrial distress, increased apoptosis in malignant cells in
an AMPK-independent manner and a depletion in pyrimidine nucleotide pools.356

While

substitution at the 5th position allows for the addition of an enzyme target, selective FRα-directed
membrane transport is compromised and RFC-transport is acquired (Figure 3.1). These studies
highlight the SAR of novel pyrrolo[2,3-d]pyrimidine antifolates . The success of PMX and the
expansion of its therapeutic range beyond lung cancer, warrants further investigation of novel
pyrrolo[2,3-d]pyrimidine antifolates. Using structure based drug design that incorporates the
recently discovered crystal structure of FRα along with the structural information of AICARFTase,
we will perhaps come closer to designing a potent FRα targeted AICARFTase inhibitor to provide
a less toxic, yet efficacious treatment option for ovarian cancer.
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Figure 3.1: “Big picture” schematic: The following schematic highlight the key concepts in this
body of work.
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ABSTRACT
THE THERAPEUTIC TARGETING OF FOLATE RECPTOR ALPHA POSITIVE
TUMORS VIA FOLATE RECEPTOR-SELECTIVE NOVEL 5-AND 6- SUBSTITUTED
PYRROLO [2,3-D] PYRIMIDINE ANTIFOLATES
by
SHERMAINE KIMBERLY MITCHELL-RYAN
May 2015
Advisor: Dr. Larry H Matherly
Major: Cancer Biology (Pharmacology)
Degree: Doctor of Philosophy
Ovarian Cancer is the fifth leading cause of cancer-related death of women in the United
States. Epithelial Ovarian Cancer (EOC) constitutes 85-90% of malignancies within the ovary,
with an alarming majority of these cases diagnosed at advanced stage. While most patients are
initially highly responsive to the current treatment standard, there is a very high probability that
they will recur with a drug resistant fatal disease. Currently there is no validated comprehensive
model of disease progression for ovarian cancer, although tremendous progress has been made in
understanding the origin of this disease and a putative precursor lesion has been identified via
molecular profiling. This progress has led to the identification of molecular signatures that not
only distinguish high grade from low grade tumors, but it also highlights mutations that are unique
to each histological type. Even though we are armed with this information and are well within the
age of molecular targeting, the treatment of ovarian cancer has remained the same for over 40
years, when the use of platinum-based therapies and taxanes were introduced.
Approximately 90 percent of EOC are folate receptor alpha (FRα) positive with the extent
of receptor over-expression corresponding with stage and grade of disease. FRα based therapies
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are a subject of increasing interest warranted by a growing number malignancies, from various
tissue types, showing FRα expression. Due to this increase of receptor expression in advanced
disease in EOC, designing FRα-targeted agents will enhance the therapeutic window in a
population of patients where most treatments fail.

The clinically approved antifolates,

methotrexate (MTX) and pemetrexed (PMX), have greatly improved treatment outcomes in a
number of malignancies, however they have been implicated in dose-limiting toxicities that are
thought to arise from uptake mediated by the ubiquitously express protein, the reduced folate
carrier (RFC). This encourages the development of novel antifolates that utilize other available
folate transport mechanisms over RFC.
In this study we explored the impact of the addition of various structural components on a
pyrrolo[2,3-d]pyrimidine scaffold and demonstrated: (1) the significance of a 5 vs 6 position
substitution on the scaffold and how it impacts the pharmacology of the compound; (2) that novel
6-substituted pyrrolo[2,3-d]pyrimidines show remarkable potencies that are mediated via FRα
membrane transport; and (3) the impact of purine salvage on the efficacy of novel antifolates.
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